

1 DNA mismatch repair gene variant classification: evaluating the 2 utility of somatic mutations and mismatch repair deficient colonic 3 crypts and endometrial glands

4 Romy Walker^{1,2*}, Khalid Mahmood^{1,2,3}, Julia Como^{1,2}, Mark Clendenning^{1,2}, Jihoon E. Joo^{1,2},
5 Peter Georgeson^{1,2}, Sharelle Joseland^{1,2}, Susan G. Preston^{1,2}, Bernard J. Pope^{1,2,3}, James M.
6 Chan^{1,2}, Rachel Austin⁴, Jasmina Bojadzieva⁵, Ainsley Campbell⁵, Emma Edwards⁶, Margaret
7 Gleeson⁷, Annabel Goodwin^{8,9}, Marion T. Harris¹⁰, Emilia Ip¹¹, Judy Kirk⁷, Julia Mansour¹²,
8 Helen Marfan⁴, Cassandra Nichols¹³, Nicholas Pachter^{13,14,15}, Abiramy Ragunathan⁷, Allan
9 Spigelman^{8,16,17}, Rachel Susman⁴, Michael Christie^{18,19}, Mark A. Jenkins^{2,20}, Rish K. Pai²¹,
10 Christophe Rosty^{1,2,22,23}, Finlay A. Macrae^{24,25,26}, Ingrid M. Winship^{24,26†}, Daniel D. Buchanan
11 ^{1,2,24†} for the ANGELS study

12
13 ¹Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive
14 Cancer Centre, The University of Melbourne, Melbourne, VIC, Australia

15 ²University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre,
16 Melbourne, VIC, Australia

17 ³Melbourne Bioinformatics, The University of Melbourne, Melbourne, VIC, Australia

18 ⁴Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia

19 ⁵Clinical Genetics Unit, Austin Health, Melbourne, VIC, Australia

20 ⁶Familial Cancer Service, Westmead Hospital, Sydney, NSW, Australia

21 ⁷Hunter Family Cancer Service, Newcastle, NSW, Australia

22 ⁸Cancer Genetics Department, Royal Prince Alfred Hospital, Camperdown, NSW, Australia

23 ⁹University of Sydney, Sydney, NSW, Australia

24 ¹⁰Monash Health Familial Cancer Centre, Clayton, VIC, Australia

25 ¹¹Cancer Genetics service, Liverpool Hospital, Liverpool, NSW, Australia

26 ¹²Tasmanian Clinical Genetics Service, Royal Hobart Hospital, Hobart, TAS, Australia

27 ¹³Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, Australia

28 ¹⁴Medical School, University of Western Australia, Perth, WA, Australia

29 ¹⁵School of Medicine, Curtin University, Perth, WA, Australia

30 ¹⁶St Vincent's Cancer Genetics Unit, Sydney, NSW, Australia

31 ¹⁷Surgical Professorial Unit, UNSW Clinical School of Clinical Medicine, Sydney, NSW,
32 Australia

33 ¹⁸Department of Medicine at Royal Melbourne Hospital, Melbourne Medical School, The
34 University of Melbourne, Melbourne, VIC, Australia

35 ¹⁹Department of Pathology, The Royal Melbourne Hospital, Melbourne, VIC, Australia

36 ²⁰Centre for Epidemiology and Biostatistics, School of Population and Global Health, The
37 University of Melbourne, Melbourne, VIC, Australia

38 ²¹Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA

39 ²²Envoi Specialist Pathologists, Brisbane, QLD, Australia

40 ²³*University of Queensland, Brisbane, QLD, Australia*

41 ²⁴*Genomic Medicine and Familial Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC,*
42 *Australia*

43 ²⁵*Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, VIC, Australia*

44 ²⁶*Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia*

45 † *These authors contributed equally to this work*

46 *Correspondence: romy.walker@unimelb.edu.au

47

48 **Simple Summary:** Lynch syndrome is caused by germline pathogenic variants in the DNA
49 mismatch repair (MMR) genes predisposing carriers to colorectal and endometrial cancer.
50 Genetic testing for Lynch syndrome, in the form of multigene panel testing, frequently identifies
51 variants of uncertain clinical significance (VUS). These VUS have limited clinical actionability
52 and create uncertainty for patients and clinicians regarding their risk of cancer. In this study, we
53 tested carriers of germline VUS for features consistent with Lynch syndrome, namely 1) tumor
54 microsatellite instability/MMR-deficiency, 2) the presence of a somatic second hit in the MMR
55 gene harboring the VUS by tumor sequencing and 3) the presence of MMR-deficiency in normal
56 colonic mucosa crypts or normal endometrial glands. Our findings showed that microsatellite
57 instability/MMR-deficiency status and somatic second hits were consistent with MMR variant
58 classifications as determined by the ACMG/InSiGHT framework. In addition to this, the
59 presence of MMR-deficient crypts/glands were consistent with pathogenic variant classification.

60

61 **Abstract:** Germline pathogenic variants in the DNA mismatch repair (MMR) genes (Lynch
62 syndrome) predispose to colorectal (CRC) and endometrial (EC) cancer. Lynch syndrome
63 specific tumor features were evaluated for their ability to support the ACMG/InSiGHT
64 framework in classifying variants of uncertain clinical significance (VUS) in the MMR genes.
65 Twenty-eight CRC or EC tumors from 25 VUS carriers (6x*MLH1*, 9x*MSH2*, 6x*MSH6*,
66 4x*PMS2*), underwent targeted tumor sequencing for the presence of microsatellite
67 instability/MMR-deficiency (MSI-H/dMMR) status and identification of a somatic MMR
68 mutation (second hit). Immunohistochemical testing for the presence of dMMR crypts/glands in
69 normal tissue was also performed. The ACMG/InSiGHT framework reclassified 7/25 (28%)
70 VUS to likely pathogenic (LP), three (12%) to benign/likely benign, and 15 (60%) VUS
71 remained unchanged. For the seven re-classified LP variants comprising nine tumors, tumor
72 sequencing confirmed MSI-H/dMMR (8/9, 88.9%) and a second hit (7/9, 77.8%). Of these LP
73 reclassified variants where normal tissue was available, the presence of a dMMR crypt/gland was
74 found in 2/4 (50%). Furthermore, a dMMR endometrial gland in a carrier of an *MSH2* exon 1-6
75 duplication provided further support for upgrade of this VUS to LP. Our study confirmed that
76 identifying these Lynch syndrome features can improve MMR variant classification, enabling
77 optimal clinical care.

78

79 **Keywords:** Lynch syndrome, DNA mismatch repair gene variant classification, DNA mismatch
80 repair deficient crypts/glands, colorectal cancer, endometrial cancer, variant of uncertain
81 significance, DNA mismatch repair gene somatic mutations

82 **1. Introduction**

83 Lynch syndrome is the most common hereditary cancer predisposition syndrome with an
84 estimated carrier frequency in the population of 1 in 280 [1] and a prevalence of up to 5% in
85 colorectal cancer (CRC) or endometrial cancer (EC) affected people [2–5]. Lynch syndrome is
86 caused by germline pathogenic variants in one of the DNA mismatch repair (MMR) genes,
87 *MLH1*, *MSH2*, *MSH6*, *PMS2* [6] or by deletions in the 3' end of the *EPCAM* gene leading to
88 transcriptional silencing of *MSH2* [7]. People with Lynch syndrome have an increased risk of not
89 only CRC and EC but also of cancers of the ovaries, stomach, duodenum, bile duct, gall bladder,
90 pancreas, urinary bladder, ureter, kidney, breast, prostate and brain tumors [8]. Current estimates
91 of penetrance for CRC vary by gene and sex but *on average* approximately one-third to one-half
92 of germline MMR pathogenic variant carriers will be diagnosed with CRC by the age of 70
93 [9,10]. Once identified, carriers of MMR gene pathogenic variants can be offered screening via
94 colonoscopy with polypectomy and other opportunities to prevent cancer development or the
95 ability to diagnose Lynch syndrome cancers at an early curable stage [11].

96 The current diagnostic approach to identify carriers of pathogenic MMR variants
97 involves immunohistochemical (IHC) testing of CRC or EC tumors for loss of MMR protein
98 expression followed by germline multigene panel testing of the MMR genes [12]. A recurring
99 outcome from genetic tests is the identification of germline variants of uncertain clinical
100 significance (VUS) in one of the MMR genes, reported to occur in 6% of the cases undergoing
101 testing for Lynch syndrome [13]. Uncertainty regarding the pathogenicity of a VUS impacts
102 clinical management, as carriers of pathogenic variants receive more intensive clinical care
103 including screening such as colonoscopy, and choice/timing of possible risk reducing surgeries,
104 than carriers of benign variants [14]. The American College of Medical Genetics and Genomics
105 (ACMG) has developed standards and guidelines for the interpretation of sequence variants
106 identified in Mendelian disorders [15]. Here, the recommendation is to classify variants into five
107 categories (class 1–5) based on available evidence deriving from variant prevalence in the
108 population, *in silico* effect prediction, functional assays and segregation data, amongst other data
109 sources [15]. Comparably, the International Society for Gastrointestinal Hereditary Tumours
110 (InSiGHT) working group determined InSiGHT criteria to aid with MMR variant classification
111 (<https://www.insight-group.org/criteria/>, last accessed date: 31st of May 2023). In this Bayesian
112 based analysis, variant pathogenicity probabilities derive from tumor characteristics and
113 predetermined combinations of evidence types to predict the variant pathogenicity likelihood
114 [16].

115 The tumor characteristics used in the InSiGHT criteria to guide MMR variant
116 classification are features commonly observed in individuals diagnosed with Lynch syndrome,
117 such as high levels of microsatellite instability (MSI-H) and MMR-deficiency (dMMR) [17], as
118 determined by MSI polymerase chain reaction (MSI-PCR) and IHC assays, respectively. MSI-
119 PCR and IHC each have their own limitations leading to false positive or false negative testing
120 results [18,19] which impedes accurate classification of MMR variants. MSI-H/dMMR tumors
121 develop in Lynch syndrome when one allele in an MMR gene becomes inactivated by a germline

122 pathogenic variant while the other allele becomes inactivated by either a somatic mutation or by
123 loss of heterozygosity (LOH). This acquisition of a somatic second hit, as described by the
124 Knudson two-hit hypothesis [20], results in complete loss of MMR function. As next-generation
125 sequencing (NGS) becomes more widely adopted for precision oncology and diagnostic
126 purposes, the ability to accurately determine MSI-H/dMMR status [21,22] and identify MMR
127 gene somatic mutations/LOH [23] using this methodology is becoming increasingly attractive as
128 a streamlined approach to diagnosing Lynch syndrome. While the strength of both the ACMG
129 guidelines and InSiGHT criteria are the ability to draw on multiple data sources, these may not
130 always be accessible in clinical settings [16]. Therefore, despite important advances,
131 classification of germline variants in the MMR genes remains challenging.

132 A novel finding in Lynch syndrome has been the identification of dMMR in
133 morphologically normal colonic crypts [24–27] or endometrial glands [28,29]. dMMR
134 crypts/glands are specific to people with Lynch syndrome, observed only in carriers and not in
135 people with sporadic MSI-H/dMMR tumors [27]. In people with Lynch syndrome the acquisition
136 of the somatic second hit in normal tissue results in biallelic inactivation of the MMR gene,
137 which is evidenced by loss of MMR protein expression as detected by IHC [24,27], representing
138 the initiation of tumorigenesis. Therefore, the presence of a dMMR crypt/gland is a strong
139 indicator of a germline MMR pathogenic variant. To date, this unique characteristic has not yet
140 been investigated for its potential application in MMR gene variant classification approaches.

141 To be most inclusive of current variant classification parameters, we applied a combination of
142 the ACMG guidelines integrated with the InSiGHT criteria, hereon referred to as the
143 ACMG/InSiGHT framework, for classification of variants in the MMR genes. MMR gene
144 variant classification has undergone substantial progress in the last decade through incorporation
145 of features unique to the Lynch syndrome phenotype. With the evolution of NGS-based
146 diagnostics, including for Lynch syndrome [30,31], the shift from tumor IHC to tumor NGS to
147 determine MSI-H/dMMR status is gaining support. Additionally, evidence of the presence of
148 dMMR crypts/glands has the potential to inform MMR gene variant classification within the
149 ACMG/InSiGHT approach. Thus, in this study, we investigated the role of 1) NGS-based MSI-
150 H/dMMR status using an additive feature combination approach as described previously [22], 2)
151 the presence of a somatic second hit (single mutation or LOH) in the MMR gene harboring the
152 VUS and 3) the presence of a dMMR crypt/gland in normal colonic or endometrial tissue, in
153 classifying 25 MMR VUS and compared this to their classification status derived from the
154 ACMG/InSiGHT framework. Determination of additional features or approaches to support
155 MMR gene variant classification will improve the diagnosis of Lynch syndrome and the
156 precision prevention of cancer in carriers.

157

158 **2. Materials and Methods**

159 *2.1 Patient Cohort*

160 Participants were men and women diagnosed with primary CRC or women diagnosed with EC
161 (n=25) who were identified by clinical genetic testing to carry a germline MMR gene VUS as

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

162 defined by the clinical testing report and subsequently referred by one of the Family Cancer
 163 Clinics across Australia to the ANGELS study (“Applying Novel Genomic approaches to Early-
 164 onset and suspected Lynch Syndrome colorectal and endometrial cancers”) between 2018 and
 165 2022 [32] (test group, n=25 carriers who developed n=28 tumors, **Table 1**). Cancer-affected
 166 relatives were recruited where possible to investigate segregation of the VUS. The patient IDs
 167 used in this manuscript are not known to anyone outside the research group and cannot be used
 168 to identify study subjects.

Family Count	Family ID	Relationship	Carrier Count	Carrier ID	Sex	VUS Count	Gene	Variant	Variant Type	Carrier Status	Tumors Sequenced	Tissue ID	Tissue	Age at Diagnosis	IHC	MLH1 Methylation	Carrier Tumors Tested in this Study	
1	F_051	Index	1	Id_051	F	1	MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - tumor 1	1	EC_051	EC	56-60	MLH1/PMS2	NEGATIVE	1	
		Index		Id_051	F		MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - tumor 2	Breast_051	Breast	46-50	NT	NT			
		Index		Id_051	F		MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - tumor 3	Duo_051	Duodenal	56-60	NT	NT			
		Index		Id_051	F		MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - poly 1	Polyp1_051	Tubulovillous adenoma	51-55	Normal	NT			
		Index		Id_051	F		MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - poly 2	Polyp2_051	Tubulovillous adenoma	56-60	Normal	NT			
		Index		Id_051	F		MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - poly 3	Polyp3_051	Tubulovillous adenoma	56-60	MLH1/PMS2	NT			
		Index		Id_051	F		MLH1	c.71_85del p.Val24_Pno28del	Inframe deletion	Proband - tumor 1	EC_161	EC	56-60	MLH1/PMS2	NEGATIVE	2		
		Index		Id_161	F		3	MSH6	c.406G_407T del p.Lys1338Aspfs*2	Frameshift	Proband - tumor 2	CRC_161	CRC	31-35	Normal	NT		
		Child		Id_161-2	M		MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier	CRC_161-2	CRC	31-35	Normal	NT			
		Sibling		Id_161-3	F		MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier - tumor 1	CRC1_161-3	CRC	36-40	NT	NT			
2	F_161	Child	3	Id_161-2	M	4	MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier - tumor 2	CRC2_161-3	CRC	61-65	MLH1/PMS2	NT			
		Sibling		Id_161-3	F		MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier - tumor 3	CR2_161-3	CRC	61-65	NT	NT			
		Sibling		Id_161-3	F		MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier - tumor 1	CR1_161-3	CRC	61-65	NT	NT			
		Sibling		Id_161-3	F		MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier - tumor 2	CR2_161-3	CRC	61-65	MLH1/PMS2	NT			
		Sibling		Id_161-3	F		MLH1	c.539_541del p.Val180del	Inframe deletion	Carrier - tumor 3	CR3_161-3	CRC	61-65	NT	NT			
		Index		Id_176	F		4	MLH1	c.1594G>C p.Gly532Arg	Missense	Proband - tumor 1	3	CRC_176	CRC	46-50	MLH1/PMS2	NEGATIVE	3
		Index		Id_176	F		MLH1	c.1594G>C p.Gly532Arg	Missense	Proband - tumor 2	4	EC_176	EC	51-55	MLH1/PMS2	NEGATIVE		
		Pa m		Id_176-2	F		MLH1	c.1594G>C p.Gly532Arg	Missense	Carrier	CRC_176-2	CRC	81-85	PMS2	NT			
		Index		Id_176	F		5	MLH1	c.1594G>A p.Gly532Asp	Missense	Proband	5	CRC_176	CRC	41-45	MLH1/PMS2	NEGATIVE	4
		Index		Id_176	F		6	MSH2	Exon 1-6 duplication	Eon duplication	Proband	6	CRC_176	CRC	26-30	MSH2/MSH6	NT	5
3	F_176	Index	5	Id_176	F	4	MLH1	c.1594G>C p.Gly532Arg	Missense	Proband - tumor 1	7	EC_058	EC	46-50	MSH2/MSH6	NT	6	
		Index		Id_058	F		MSH2	Exon 1-6 duplication	Eon duplication	Proband - tumor 2	8	EC_058	EC	46-50	NT	NT		
		Index		Id_058	F		MSH2	Exon 1-6 duplication	Eon duplication	Proband - tumor 2	9	EC_058	EC	46-50	NT	NT		
		Child		Id_058-2	F		MSH2	Exon 1-6 duplication	Eon duplication	Carrier	Polyp_058-2	Polyp	16-20	NT	NT			
		Pa m		Id_058-3	F		MSH2	Exon 1-6 duplication	Eon duplication	Carrier - tumor 1	CR1_058-3	CRC	51-55	NT	NT			
		Pa m		Id_058-3	F		MSH2	Exon 1-6 duplication	Eon duplication	Carrier - tumor 2	CR2_058-3	CRC	51-55	NT	NT			
		Re b tie		Id_058-4	M		MSH2	Exon 1-6 duplication	Eon duplication	Obligate carrier - tumor 1	CR2_058-4	CRC	71-75	NT	NT			
		Re b tie		Id_058-4	M		MSH2	Exon 1-6 duplication	Eon duplication	Obligate carrier - tumor 2	CR2_058-4	CRC	71-75	NT	NT			
		Re b tie		Id_058-5	F		MSH2	Exon 1-6 duplication	Eon duplication	Carrier	CR2_058-5	CRC	71-75	NT	NT			
		Re b tie		Id_058-5	F		MSH2	Exon 1-6 duplication	Eon duplication	Carrier	CR2_058-5	CRC	71-75	NT	NT			
4	F_149	Index	14	Id_149	M	8	MSH2	Exon 14-15 duplication	Eon duplication	Proband	8	CRC_149	CRC	26-30	MSH2/MSH6	NT	7	
		Pa m		Id_149-2	F		MSH2	Exon 14-15 duplication	Eon duplication	Carrier	CRC_149-2	CRC	46-50	NT	NT			
		Index		Id_138	M		9	MSH2	c.328A>C p.Lys110Gln	Missense	Proband - tumor 1	9	CRC_138	CRC	66-70	MSH2/MSH6	NT	8
		Index		Id_138	M		MSH2	c.328A>C p.Lys110Gln	Missense	Proband - tumor 2	CRC_138	CRC	76-80	NT	NT			
		Sibling		Id_138-2	M		MSH2	c.328A>C p.Lys110Gln	Missense	Carrier - tumor 1	5 kin_138-2	Skin (melanoma)	41-45	NT	NT			
		Sibling		Id_138-2	M		MSH2	c.328A>C p.Lys110Gln	Missense	Carrier - tumor 2	CRC_138-2	CRC	61-65	Normal	NT			
		Sibling		Id_138-2	M		MSH2	c.328A>C p.Lys110Gln	Missense	Carrier - tumor 3	Pa_n_138-2	Pancreatic	76-80	Normal	NT			
		Sibling		Id_138-2	M		MSH2	c.328A>C p.Lys110Gln	Missense	Carrier - tumor 1	10	EC_135	EC	61-65	MSH2/MSH6	NT	9	
		Sibling		Id_135	F		10	MSH2	c.1862G>T p.Arg611Ileu	Missense	Proband - tumor 2	11	CRC_135	CRC	36-40	NT	NT	
		Sibling		Id_135-2	F		MSH2	c.1862G>T p.Arg611Ileu	Missense	Carrier - tumor 1	11	EC_135-2	EC	56-60	MLH1/PMS2*	POSITIVE	10	
5	F_135	Sibling	18	Id_135-2	F	10	MSH2	c.1862G>T p.Arg611Ileu	Missense	Carrier - poly 1	12	EC_008	EC	56-60	NT	NT		
		Index		Id_008	F		11	MSH2	c.2005A>T_2005A>T44del	Splice	Proband - tumor 1	12	EC_008	EC	61-65	MSH2/MSH6	NT	11
		Index		Id_008	F		MSH2	c.2005A>T_2005A>T44del	Splice	Proband - tumor 2	13	Uteru_L_008	Uterus	41-45	NT	NT		
		Index		Id_008	F		MSH2	c.2005A>T_2005A>T44del	Splice	Proband - tumor 3	14	CRC_008	CRC	51-55	NT	NT		
		Index		Id_132	F		12	MSH2	c.2060T>C p.Leu677Prol	Missense	Proband	13	CRC_132	CRC	36-40	MSH2/MSH6	NT	12
		Index		Id_156	F		13	MSH6	c.3556A>G_3556A>G86ins p.2	Splice	Proband - tumor 1	14	CRC_156	CRC	61-65	MSH6	NT	13
		Index		Id_156	F		MSH6	c.3556A>G_3556A>G86ins p.2	Splice	Proband - tumor 2	15	EC_156	EC	51-55	MSH6	NT		
		Sibling		Id_156-2	M		MSH6	c.3556A>G_3556A>G86ins p.2	Splice	Carrier	NA	Unaffected	Unknown	NT	NT			
		Index		Id_143	F		14	PMS2	c.1376G>T p.Ser461Ile	Missense	Proband	16	EC_143	EC	26-30	PMS2	NEGATIVE	14
		Sibling		Id_143-2	M		PMS2	c.1376G>T p.Ser461Ile	Missense	Carrier	NA	Unaffected	Unknown	NT	NT			
6	F_143	Pa m	26	Id_143-3	M	15	PMS2	c.1376G>T p.Ser461Ile	Missense	Carrier	NA	Unaffected	Unknown	NT	NT			
		Re b tie		Id_143-4	F		PMS2	c.1376G>T p.Ser461Ile	Missense	Carrier	NA	Unaffected	Unknown	NT	NT			
		Re b tie		Id_143-5	F		PMS2	c.1376G>T p.Ser461Ile	Missense	Carrier	NA	Unaffected	Unknown	NT	NT			
		Re b tie		Id_143-6	F		PMS2	c.1376G>T p.Ser461Ile	Missense	Carrier	NA	Unaffected	Unknown	NT	NT			
		Re b tie		Id_143-7	F		PMS2	c.1376G>T p.Ser461Ile	Missense	Carrier	NA	Unaffected	Unknown	NT	NT			
		Re b tie		Id_143-8	F		PMS2	c.1376G>T p.Ser461Ile	Missense	Obligate carrier	NA	Unaffected	Unknown	NT	NT			
		Index		Id_138	F		15	MLH1	c.1133C>T p.Arg383Cys	Missense	Proband - tumor 1	17	CRC_138	CRC	43-45	MSH2/MSH6	NT	15
		Index		Id_202	F		16	MSH2	c.138C>G p.His466Ile	Missense	Proband - tumor 1	18	EC_202	EC	61-65	MSH6	NT	16
		Index		Id_202	F		MSH2	c.138C>G p.His466Ile	Missense	Proband - tumor 2	19	Breast_202	Breast	61-65	NT	NT		
		Index		Id_395	F		17	MSH2	c.668T>C p.Leu223Prol	Missense	Proband	20	CRC_395	CRC	36-40	MLH1/PMS2	NEGATIVE	17
Index	Id_089	F	18	MSH6	c.2827G>T p.As p943Tyr	Missense	Proband - tumor 1	20	CRC_1_089	CRC	41-45	MLH1/PMS2	NEGATIVE	18				
Index	Id_089	F	MSH6	c.2827G>T p.As p943Tyr	Missense	Proband - tumor 2	21	CRC_089	CRC	41-45	NT	NT						
Index	Id_046	F	19	MSH6	c.2295A>G p.As p884Ileu	Missense	Proband	22	EC_046	EC	66-70	PMS2	NEGATIVE	19				
Index	Id_263	F	20	MSH6	c.785T>A p.?	5' UTR	Proband	22	EC_263	EC	61-65	MLH1/PMS2	NEGATIVE	20				
Index	Id_193	M	21	PMS2	c.2149G>A p.Val171Met	Missense	Proband	23	CRC_193	CRC	31-35	MLH1/PMS2	NEGATIVE	21				
Index	Id_170	F	22	MLH1	c.117G>T p.?	5' UTR	Proband	24	CRC_170	CRC	31-35	Normal	NEGATIVE	22				
Index	Id_111	F	23	MSH6	c.1153_1155del p.Arg383del	Inframe deletion	Proband	25	CRC_111	CRC	36-40	Normal	NT	23				
Index	Id_240	F	24	PMS2	c.2315G>A p.Gly779Arg	Missense	Proband	26	CRC_240	CRC	26-30	Normal	NEGATIVE	24				
Index	Id_352	M	25	PMS2	c.2416A p.Gln811ys	Missense	Proband - tumor 1	27	CRC_1_352	CRC	56-60	Normal	NT	25				
Index	Id_352	M	PMS2	c.2416A p.Gln811ys	Missense	Proband - tumor 2	28	CRC_2_352	CRC	56-60	MSH2/MSH6	NT						
Index	Id_352	M	PMS2	c.2416A p.Gln811ys	Missense	Proband - tumor 3	29	Breast_352	Glioblastoma	51-55	NT	NT						

169

170 **Table 1.** List of carriers of a germline DNA mismatch repair variant of uncertain clinical
 171 significance and their cancer-affected status that were included in this study. Abbreviations: ID,
 172 identification number; F, female; M, male; VUS, variant of uncertain clinical significance; CRC,
 173 colorectal cancer; EC, endometrial cancer; IHC, immunohistochemistry; NA, not applicable; NT,
 174 not tested; UTR, untranslated region.

175 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

176 ¹ Family members (F_161) were only tested for the germline *MLH1* c.539_541del p.(Val180del)
177 variant and not for the concomitant *MSH6* c.4068_4071dup p.(Lys1358Aspfs*2) variant

178 ² The parents (ID_376-2 and ID_376-3) from carrier ID_376 were tested for the germline *MSH2*
179 exon 1-6 duplication and were found to be wildtype

180 ³ The sister (ID_058-3) and relative (ID_058-7) from carrier ID_058 were tested for the germline
181 *MSH2* exon 1-6 duplication and were found to be wildtype

182 ⁴ Participant ID_149 carries a germline *MSH2* exon 14-15 duplication and a concomitant
183 germline *POLE* c.1708C>A p.(Leu570Met) variant

184 ⁵ The mother (ID_149-2) from carrier ID_149 was tested for the familial germline *MSH2* exon
185 14-15 duplication and *POLE* c.1708C>A p.(Leu570Met) variants, however, was found to only
186 carry the *MSH2* germline VUS

187

188 A biopsy or resection tumor tissue specimen was collected from each participant. Normal
189 colonic mucosa or normal endometrium tissue were collected where possible. Pedigree
190 information was collected during clinical work-up and segregation of the MMR VUS in family
191 members was performed via Sanger sequencing as part of this study. A group of CRC- or EC-
192 affected MMR pathogenic variant carriers (n=19) or non-carriers of a germline MMR pathogenic
193 variant or VUS (n=20) who were participants of the Australasian Colorectal Cancer Family
194 Registry (ACCFR) were included as reference groups, where n=37 underwent targeted panel
195 sequencing or whole exome sequencing as shown in **Table S1**. The molecular and phenotypic
196 characterization of these individuals and their tumors from the ANGELS [22,32,33] and the
197 ACCFR [2,34–36] have been described previously. All studies were approved by the Human
198 Research Ethics Committees at The University of Melbourne (HREC#1750748) and hospitals
199 governing participating family cancer clinics. Written informed consent was obtained from all
200 participants.

201

202 *2.2 Immunohistochemical Testing for DNA Mismatch Repair Protein Expression*

203 For the 25 MMR VUS carriers, IHC of tumor tissue was derived from either the diagnostic
204 pathology report or from testing performed by this study. For this study, the Ventana
205 *DISCOVERY ULTRA* automated stainer (Ventana Medical Systems Inc., Oro Valley, United
206 States) was used with anti-MLH1 (M1), anti-MSH2 (G219-1129), anti-MSH6 (SP93) mouse
207 monoclonal and anti-PMS2 (A16-4) rabbit monoclonal primary antibodies (Roche Diagnostics,
208 Basel, Switzerland) and tested on a 4µM tissue section. All staining protocols were performed
209 following the manufacturer's protocol (Roche Diagnostics).

210 To detect dMMR colonic crypts or endometrial glands, IHC was performed on 4µM
211 sections from a tissue block containing non-tumor-adjacent normal colonic mucosa or
212 endometrium from the resection margins. Twenty serial 4µM sections were cut to a depth of
213 80µM with the 1st, 10th and 19th slide stained for the MMR protein that was concordant with the
214 MMR gene harboring the VUS. If no dMMR crypt/gland was identified, a further twenty 4µM
215 sections were cut and screened. This process was repeated up to three times with a maximum of

216 3x80 μ M sections of tissue screened. When a dMMR crypt/gland was identified, the subsequent
217 section (2nd, 11th or 20th slide) was stained for the unaffected MMR gene as a control for
218 artefactual loss of expression. For example, if an MSH2-deficient crypt/gland was identified, the
219 next slide was stained for MLH1 protein expression. All dMMR crypts/glands identified in this
220 study were independently confirmed by two senior pathologists (CR and RP), with 100%
221 concordance in classifying stained slides as positive or negative for dMMR crypts/glands. Six
222 normal colonic mucosa and six normal endometrial tissue samples were available for a total of
223 12 VUS carriers.

224

225 2.3 Tumor *MLH1* Methylation Testing Assays

226 Testing for *MLH1* gene promoter methylation on formalin-fixed paraffin embedded (FFPE)
227 tissue DNA was performed as previously described [22,33]. Briefly, two independent *MLH1*
228 methylation assays, namely MethyLight [2,34] and MS-HRM (methylation-sensitive high
229 resolution melting assay) [37], were used to test the same tumor DNA sample alongside a set of
230 DNA standards (0% - 100% methylation) and no-template (negative) controls. Bisulfite
231 conversion of tumor DNA was performed using the EZ DNA Methylation-LightningTM Kit
232 (Zymo Research, Irvine, United States). For MethyLight, *MLH1* methylation was quantitatively
233 reported based on the percentage of methylated reference (PMR) calculations [34], where tumors
234 with a PMR \geq 10% were considered “positive” [2,34]. For MS-HRM, the MeltDoctorTM HRM
235 Reagent Kit (Thermo Fisher Scientific, Massachusetts, United States) was used where tumors
236 demonstrating \geq 5% were considered *MLH1* methylation “positive”.

237

238 2.4 Next-Generation Sequencing

239 All available FFPE tumor tissue DNA (n=28) and matched blood-derived DNA samples from 25
240 MMR VUS carriers (**Table 2**) underwent targeted multigene panel sequencing using the panel
241 capture previously described [22,33]. This customized panel incorporated 297 genes, including
242 the MMR and *EPCAM* genes, as well as other established hereditary CRC and EC genes and the
243 *BRAF* p.V600E mutation (2.005 megabases). Library preparation was performed using the
244 SureSelectTM Low Input Target Enrichment System from Agilent Technologies (Santa Clara,
245 California, United States) using standard procedures. The median on-target coverage for the
246 panel sequenced test tumors was 906 (interquartile range = 763 – 1099) for the tumor DNA and
247 154 (interquartile range = 128 – 172) for blood-derived DNA samples. Panel libraries were
248 sequenced on an Illumina NovaSeq 6000 (San Diego, California, United States) comprising 150
249 base pair (bp) paired end reads performed at the Australian Genome Research Facility.

				Incorporation of Tumor Data from this Study							Incorporation of External Tumor Data							ACMG/InSiGHT Classification		
				#	Gene	Variant	Variant Type	ClinVar Variant ID	gnomAD (<1 in 50,000 alleles)	Age at Diagnosis	MSI/MMR Status	Tumor BRAF V600E Mutation Status	Tumor MLH1 Methylation Status	IHC	Total No. of Tumors with IHC Concordant to Germline VUS	Total No. of Tumors with IHC Discordant to Germline VUS	Total No. of Families with Germline MMR VUS Tested		Prior Probability for Pathogenicity (MAPP / PP2 score)	Tumor Characteristics Odds of Pathogenicity
MMR VUS CONCORDANT TO IHC PATTERN OF LOSS	1	MLH1	c.71_85del p.(Val24_Pro28del)	Inframe deletion	NA	0	56-60	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	1	0	1	NA	0.41	None	NA	0.02	Class 3: VUS
	2	MLH1	c.539_541del p.(Val180del)	Inframe deletion	185186	0	56-60	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	1	0	1	NA	0.41	None	NA	0.01	Class 3: VUS
	3	MLH1	c.1594G>C p.(Gly532Arg)	Missense	NA	0	46-50, 51-55	MSI-H / dMMR (5/6) (1x), MSI-H / dMMR (6/6) (1x)	WT (2x)	Negative (2x)	MLH1/PMS2 (1x), MLH1/PMS2 (1x)	2	0	1	0.96	6.52	None	NA	0.01	Class 3: VUS
	4	MLH1	c.1595G>A p.(Gly532Asp)	Missense	976474	0	41-45	MSI-H / dMMR (5/6)	WT	Negative	MLH1/PMS2	3	0	5	0.96	153.04	None	1.96	0.01	Class 4: LP
	5&6	MSH2	Duplication exon 1-6 ¹	Exon duplication	NA	0	26-30, 46-50	MSI-H / dMMR (6/6) (2x)	WT (2x)	NT	MSH2/MSH6 (2x)	2	0	2	NA	42.51	None	NA	NA	Class 3: VUS
	7	MSH2	Duplication exon 14-15	Exon duplication	NA	0	26-30	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	1	0	1	NA	6.52	None	NA	NA	Class 4: LP
	8	MSH2	c.328A>C p.(Lys110Gln)	Missense	127642	0.00000398	66-70	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	1	0	1	0.06	4.06	None	NA	0.01	Class 3: VUS
	9	MSH2	c.1862G>T p.(Arg621Leu)	Missense	218040	0.0000319	61-65	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	5	0	5	0.85	1103.14	None	1.32	0	Class 4: LP
	10	MSH2	c.2005+3_2005+14del	Splice	90842	0	51-55	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	2	0	2	0.26	16.48	None	1.44	0.57	Class 4: LP
	11	MSH2	c.2060T>C p.(Leu687Pro)	Missense	90873	0	36-40	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	1	0	>1 ²	0.96	6.52	None	NA	0	Class 4: LP
	12	MSH6	c.3556+5_3556+8delins	Splice	NA	0	61-65	MSI-H / dMMR (5/6)	WT	NT	MSH6	3	0	3	0.26	66.92	None	NA	0	Class 4: LP
	13	PMS2	c.137G>T p.(Ser46Ile)	Missense	9245	0.000163	26-30	MSI-H / dMMR (6/6)	WT	Negative	PMS2	2	0	2	0.939	0.65	None	3.083	0.03	Class 4: LP
	14	MLH1	c.1153C>T p.(Arg385Cys)	Missense	89653	0.0000597	41-45	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	0	1	2	0.937	0.01	None	9.45	0.03	Class 3: VUS
	15	MSH2	c.138C>G p.(His46Gln)	Missense	90654	0.000218	61-65	MSI-H / dMMR (3/6)	WT	NT	MSH6	1	3	4	0.74	0.00014	None	0.14	0	Class 2: LB
	16	MSH2	c.668T>C p.(Leu223Pro)	Missense	408456	0	36-40	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	0	1	1	0.525	0.11	None	NA	0	Class 3: VUS
	17	MSH6	c.2827G>C p.(Asp943Tyr)	Missense	142495	0.000046	41-45	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	0	1	1	0.05	0.11	None	NA	0	Class 3: VUS
	18	MSH6	c.2950A>C p.(Asn984His)	Missense	186492	0.0000479	66-70	MSI-H / dMMR (4/6)	WT	Negative	PMS2	0	1	1	0.005	0.11	None	NA	0	Class 3: VUS
	19	MSH6	c.4068_4071dup p.(Lys1358Aspfs*2)	Frameshift	89518	0	56-60	MSI-H / dMMR (6/6)	WT	-	MLH1/PMS2	1	0	1	NA	4.06	None	NA	0.1	Class 2: LB
	20	MSH6	c.*85T>A	3' UTR	89155	0.00786	61-65	MSI-H / dMMR (5/6)	WT	Negative	MLH1/PMS2	0	4	4	0	0	None	NA	0	Class 1: B
	21	PMS2	c.2149G>A p.(Val717Met)	Missense	41709	0.000758	31-35	MSI-H / dMMR (5/6)	WT	Negative	MLH1/PMS2	2	0	2	0.595	26.47	None	0.308	0	Class 3: VUS
	NO MMR IHC LOSS	22	MLH1	c.-117G>T	5' UTR	344901	0	31-35	MSI-H / dMMR (3/6)	WT	NT	Normal	0	1	1	NA	0.11	None	NA	0.07
23		MSH6	c.1153_1155del p.(Arg385del)	Inframe deletion	89177	0	36-40	MSI-H / dMMR (5/6)	WT	NT	Normal	1	1	4	0.5	0.46	None	15.22	0	Class 3: VUS
24		PMS2	c.2335G>A p.(Gly779Arg)	Missense	127778	0.00000799	26-30	MSS / pMMR (1/6)	WT	Negative	Normal	1	0	1	0.96	0.11	None	NA	0.03	Class 3: VUS
25		PMS2	c.241G>A p.(Glu181Lys)	Missense	182817	0.0000159	56-60	MSI-H / dMMR (5/6) (1x), MSS / pMMR (1/6) (1x)	WT (2x)	NT	MSH2/MSH6 (1x), Normal (1x)	0	2	2	0.045	0.02	None	NA	0	Class 3: VUS

250

251 **Table 2.** Display of the data used to implement the ACMG/InSiGHT framework for final DNA mismatch repair variant of uncertain
252 significance classification. Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; MMR, DNA mismatch repair;
253 dMMR, DNA mismatch repair deficiency; pMMR, DNA mismatch repair proficiency; WT, wildtype; IHC, immunohistochemistry;
254 MAPP, multi-variate analysis of protein polymorphisms; PP2, PolyPhen-2.1; VUS, variant of uncertain clinical significance; LB,
255 likely benign; LP, likely pathogenic; NA, not applicable; NT, not tested.

256 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

257 ¹ Two unrelated families (F_058 and F_376) who carry the *MSH2* exon 1-6 duplication were grouped together for the purposes of the
258 ACMG/InSiGHT classification, however, at this stage without further investigation, it remains unknown if the breaking points of the
259 variants identified in each family are in the same location

260 ² Multiple entries documented in Ambry Genetics (<https://www.ambrygen.com/>, last accessed date: 23rd of May 2023)

261

262 2.5 Bioinformatics Pipeline

263 Adapter sequences were trimmed from raw FASTQ files using trimmomatic (v.0.38) [38] and
264 aligned to the GRCh37 human reference genome using Burrows-Wheeler-Aligner (v.0.7.12) to
265 generate BAM files. Germline and somatic single nucleotide variants and somatic insertions /
266 deletions (INDELs) were called using Strelka (v.2.9.2., Illumina, San Diego, California, United
267 States) and Mutect2 (v.0.5) using the recommended workflows [39,40]. Tumor mutational
268 signatures (TMS) were calculated using the pre-defined set of 18 small (1-50bp)
269 insertions/deletions (ID) signatures as published on COSMIC
270 (<https://cancer.sanger.ac.uk/signatures/>, last accessed date: 13th of January 2023, v.3.2) [41]. All
271 variants were restricted to the panel capture region and filtered based on PASS variants called by
272 both Strelka and Mutect2. All variants were further filtered on a minimum depth of 50bp for
273 normal/blood and tumor samples with a minimum variant allele frequency of 10% [32]. For
274 variant calling, the following RefSeq transcripts were used (*MLH1*: NM_000249.3, *MSH2*:
275 NM_000251.2, *MSH6*: NM_000179.2 and *PMS2*: NM_000535.5). The MMR genes were
276 interrogated for somatic mutations, including single somatic mutations (e.g. missense, nonsense,
277 insertion, deletion, frameshift variant type) and LOH, in the same gene as the germline MMR
278 VUS. LOH across the MMR genes were called using LOHdeTerminator (v.0.6,
279 <https://github.com/supernifty/LOHdeTerminator>). The pathogenicity of somatic MMR mutations
280 were determined using the Varsome database [42] (<https://varsome.com/>, last accessed date: 13th
281 of January 2023), which categorizes variants into the ACMG classification system. All likely
282 pathogenic/pathogenic MMR mutations were manually confirmed in BAM files using the
283 Integrative Genomics Viewer (v.2.3) [43].

284

285 2.6 Determination of Tumor Microsatellite Instability and Mismatch Repair Deficiency

286 Panel sequenced tumors were assessed for evidence of MSI-H/dMMR using: 1) four independent
287 MSI detection tools, namely MSMuTect [44], MANTIS [45], MSIseq [46] and MSISensor [47],
288 2) INDEL count and 3) the combination of ID2 TMS with ID7 TMS (TMS ID2+ID7) [32] as
289 described in Walker *et al.* 2023 [22]. Overall tumor MSI-H/dMMR status was determined by
290 combining these six features (using an additive feature combination approach), where a tumor
291 with any 3 or more of these 6 features with positivity for dMMR was considered to be MSI-
292 H/dMMR [22]. This approach has been shown to be the most robust across whole-exome
293 sequencing and panel assays as well as across CRC and EC tumors, while presenting with the
294 highest prediction accuracy to differentiate dMMR from pMMR (MMR-proficient) tumors [22].

295

296 2.7 Classifying MMR Variants Using a Combination of Existing Methodologies

297 We used a combination of the ACMG [15] and InSiGHT [16] criteria, hereon referred to as the
298 ACMG/InSiGHT framework, for improved and contemporary variant classification. Briefly, the
299 features assessed are displayed in **Table 2**, including:

- 300 • Rarity of MMR variant (the rarer a variant, the more likely the variant will not be present
301 in healthy controls, with <1 in 50,000 alleles indicating MMR variant rarity in gnomAD
302 using the non-cancer dataset.);
- 303 • Incorporation of tumor characteristics generated by this study, including age of diagnosis,
304 tumor NGS-derived MSI-H/dMMR status, tumor *BRAF* V600E mutation status, tumor
305 *MLH1* methylation status and MMR IHC result;
- 306 • Prior probability scores calculated for missense variants using the *in silico* prediction
307 tools Multi-variate Analysis of Protein Polymorphisms [48] and PolyPhen-2.1 [49] (pre-
308 computed prior probabilities with a score of >0.68 and ≤0.81 indicate variant
309 pathogenicity as determined in <https://hci-priors.hci.utah.edu/PRIORS/> (last accessed
310 date: 18th of July 2023);
- 311 • Tumor characteristics, either generated from this study or available from external public
312 data, for the same variant were combined to generate a tumor odds pathogenicity score
313 [50,51];
- 314 • Evidence of functional effect on protein structure (e.g., ClinVar,
315 <https://www.ncbi.nlm.nih.gov/clinvar/>, last accessed date: 1st of June 2023);
- 316 • Co-segregation of variant with disease phenotype with a combined Bayes Likelihood
317 Ratio >18.7 in two or more families [16] (e.g., COsegregation v.2: [https://fengbj-
318 laboratory.org/cool2/manual.html](https://fengbj-laboratory.org/cool2/manual.html), last accessed date: 1st of June 2023);
- 319 • Predicted splicing effect using SpliceAI (with a delta score of >0.2 indicating
320 pathogenicity) (<https://spliceailookup.broadinstitute.org/>, last accessed date: 1st of June
321 2023) [52].
- 322 • These parameters were cumulatively considered for final MMR variant classification and
323 variants were categorized into the recommended five-tier ACMG classifications (class 5
324 – pathogenic (P), class 4 – likely pathogenic (LP), class 3 – variant of uncertain
325 significance (VUS), class 2 – likely benign (LB), class 1 – benign (B)) [15]. The final
326 ACMG/InSiGHT classification for each of the 25 MMR VUS was then assessed for
327 concordance with the tumor NGS-derived MSI-H/dMMR status, somatic second hit and
328 dMMR crypt/gland testing results.


329

330 **3. Results**

331 *3.1 Characteristics of Patients with MMR VUS*

332 An overview of the study design is shown in **Figure 1**. A total of 24 carrier families with 25
333 unique germline MMR VUS were included in the study comprising VUS in *MLH1* (n=6), *MSH2*
334 (n=9), *MSH6* (n=6) and *PMS2* (n=4) with 14/25 (56%) VUS resulting in missense changes
335 (**Table 1, Table 2**). Testing for segregation of the VUS in relatives identified an additional 18
336 carriers, where the cancer-affected status of each of the 42 germline VUS carriers (probands and
337 relatives) included in the study are shown in **Table 1**. The tumor type and age at diagnosis
338 (ranging from 15-20 and 81-85 years) for each of the carriers are listed in **Table 1**, where 16/42
339 (38.1%) carriers developed multiple tumors. The pedigree for each of the VUS carrying families

340 can be requested from the corresponding author upon reasonable request. For 25/42 (59.5%)
341 VUS carriers in this study, we tested one or more tumors (**Table 1**). The pattern of loss of MMR
342 protein expression by IHC was concordant with the MMR gene harboring the VUS in 13/25
343 (52%) of the cases, discordant in 8/25 (32%) of the cases, while for a further four carriers (16%),
344 no loss of MMR protein expression by IHC was reported (pMMR) (**Table 1, Table 2**).



345
346 **Figure 1.** Overview of study design. Schema presenting the study inclusion criteria, the
347 breakdown of the germline MMR VUS distribution and the testing assays applied.
348 *Abbreviations:* CRC, colorectal cancer; EC, endometrial cancer; MMR, DNA mismatch repair;
349 VUS, variant of uncertain clinical significance; IHC, immunohistochemistry; MSI, microsatellite
350 instability; MSI-H, high levels of microsatellite instability; MSS, microsatellite stable; dMMR,
351 DNA mismatch repair deficiency; pMMR, DNA mismatch repair proficiency; ACMG, American
352 College of Medical Genetics and Genomics; InSiGHT, International Society for Gastrointestinal
353 Hereditary Tumours.

354

355 3.2 Variant Classification Using the ACMG/InSiGHT Framework

356 The re-classification of the 25 MMR VUS based on the ACMG/InSiGHT framework (see
357 Methods above) are shown in **Table 2**. A total of 10/25 (40%) VUS were reclassified, with seven

358 VUS (28%) reclassified as likely pathogenic (class 4), all of which showed a concordant pattern
359 of MMR protein loss of expression by IHC. Two out of 25 (8%) were reclassified as likely
360 benign (class 2) and one VUS was reclassified as benign (class 1), where each of the three LB/B
361 variants had a pattern of MMR protein loss that was discordant with the MMR gene harboring
362 the variant (**Table 2**). None of the VUS were categorized as pathogenic (class 5). For the
363 remaining 15 VUS, the additional information provided by this study did not change their
364 classification as a class 3 variant. Of these, six VUS were concordant with the observed IHC
365 pattern of loss, five VUS were discordant to the observed IHC pattern of loss, with four VUS
366 displaying no MMR protein loss by IHC (pMMR) (**Table 2**).

367
368 *3.3 Determining Microsatellite Instability / DNA Mismatch Repair Deficiency using Tumor*
369 *Sequencing Data*

370 To assess whether tumor features and somatic profiles generated using tumor panel sequencing
371 could inform MMR VUS classification, tumor features associated with Lynch syndrome were
372 assessed on 28 tumors collected from the 25 VUS carriers in this study (**Table 1**), and compared
373 with a reference group of dMMR tumors from known germline MMR pathogenic variant carriers
374 (n=16) and pMMR tumors from non-MMR carriers (n=18) that previously underwent tumor
375 panel sequencing (**Table S1**). The aim was to determine tumor MSI/MMR status from NGS by
376 applying the previously described additive feature combination approach [22] and compare this
377 with the observed MMR IHC status. For the reference group of tumors, the MSI/MMR status
378 from tumor sequencing was 100% concordant with the MMR IHC dMMR or pMMR result. As
379 expected for the Lynch syndrome tumors, the pattern of MMR protein loss was concordant with
380 the MMR gene harboring the germline pathogenic variant and all were MSI-H/dMMR by tumor
381 sequencing (**Table S1, Figure S1A**). In the test group of 28 tumors from 25 VUS carriers, 25/28
382 were classified as MSI-H/dMMR from tumor sequencing, of which 23/25 (92%) were dMMR by
383 MMR IHC (**Table 3, Figure S1B**). Three tumors were classified as MSS/pMMR from tumor
384 sequencing with two (66%) of these also confirmed to be pMMR by MMR IHC (**Table 3,**
385 **Figure S1B**). All 7 of the VUS reclassified by ACMG/InSiGHT framework to LP had at least
386 one tumor that was MSI-H/dMMR (**Table 3**). There were an additional 8 tumors from 7 VUS
387 carriers that were not reclassified by ACMG/InSiGHT framework that were MSI-H/dMMR from
388 tumor sequencing and demonstrated loss of the MMR protein/s concordant with the MMR gene
389 harboring the VUS (**Table 3**).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

#	Carrier ID	Tissue ID	Germline MMR VUS			ACMG/ INSIGHT Classification	Tumor Molecular Data			Lynch Syndrome Associated Tissue Features			Final Tumour Classification
			Gene	Base Change	Protein Change		Tissue	IHC	MLH1 Methylation	MSI/MMR Status by Additive Feature Approach	Presence of a Somatic Second Hit in MMR Gene Harboring VUS	Presence of a Somatic Mutation NOT in MMR Gene Harboring VUS	
1	ID_326	CRC_326	MLH1	c.159 T>G>A	p.Gly532Asp	Class 4: LP	CRC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 5/6	1x LOH MLH1	None	dMMR - VUS + 2nd hit MLH1
2	ID_149	CRC_349	MSH2	Exon 14-15 duplication	p.?	Class 4: LP	CRC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	1x mut. MSH2	None	dMMR - VUS + 2nd hit MSH2
3	ID_315	EC_315	MSH2	c.186 T>G>T	p.Arg621Leu	Class 4: LP	EC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	1x mut. MSH2	1x mut. PMS2	dMMR - VUS + 2nd hit MSH2
4	ID_315-2	EC_315-2	MSH2	c.186 T>G>T	p.Arg621Leu	Class 4: LP	EC	MLH1/PMS2 ¹	POSITIVE	MSS / pMMR 10/6	None	None	dMMR - MLH1 methylation
5	ID_008	EC_008	MSH2	c.200 S>L_200 S>L del	p.?	Class 4: LP	EC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	1x LOH MSH2	1x mut. PMS2	dMMR - VUS + 2nd hit MSH2
6	ID_132	CRC_132	MSH2	c.206 T>C	p.Leu487Pro	Class 4: LP	CRC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	1x mut. MSH2	None	dMMR - VUS + 2nd hit MSH2
7	ID_156	CRC_156	MSH6	c.3556+5_3556+8 del ins	p.?	Class 4: LP	CRC	MSH6	NT	MSI-H / dMMR 5/6	1x mut. MSH6	None	dMMR - VUS + 2nd hit MSH6
8		EC_156				Class 4: LP	EC	MSH6	NT	MSI-H / dMMR 3/6	None	None	dMMR - VUS MSH6
9	ID_143	EC_143	PMS2	c.137 G>T	p.Ser46Ile	Class 4: LP	EC	PMS2	NEGATIVE	MSI-H / dMMR 6/6	2x mut. PMS2	2x mut. MLH1	dMMR - VUS + 2nd hit PMS2
10	ID_161 ¹	EC_161	MLH1	c.539_541 del	p.Val180del	Class 3: VUS	EC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 6/6	1x mut. MLH1	None	dMMR - VUS + 2nd hit MLH1
11	ID_051	EC_051	MLH1	c.71_85 del	p.Val124_Pro28del	Class 3: VUS	EC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 6/6	1x LOH MLH1 and 1x mut. MLH1	1x mut. MSH6	dMMR - VUS + 2nd hit MLH1
12	ID_176	CRC_176	MLH1	c.159 A>G>C	p.Gly532Arg	Class 3: VUS	CRC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 6/6	1x LOH MLH1	1x mut. MSH6	dMMR - VUS + 2nd hit MLH1
13		EC_176				Class 3: VUS	EC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 5/6	2x mut. MLH1	1x mut. MSH6	dMMR - VUS + 2nd hit MLH1
14	ID_058	EC_058	MSH2	Exon 1-6 duplication	p.?	Class 3: VUS	EC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	1x LOH MSH2	None	dMMR - VUS + 2nd hit MSH2
15	ID_138	CRC_138	MSH2	c.328 A>C	p.Lys110Gln	Class 3: VUS	CRC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	2x mut. MSH2	2x mut. MSH6	dMMR - VUS + 2nd hit MSH2
16	ID_170	CRC_170	MLH1	c.117 G>T	p.?	Class 3: VUS	CRC	Normal	NEGATIVE	MSI-H / dMMR 3/6	1x LOH MLH1	None	dMMR - VUS + 2nd hit MLH1
17	ID_111	CRC_111	MSH6	c.1153_1155 del	p.Arg385del	Class 3: VUS	CRC	Normal	NT	MSI-H / dMMR 5/6	1x LOH MSH6	None	dMMR - VUS + 2nd hit MSH6
18	ID_376	CRC_376	MSH2	Exon 1-6 duplication	p.?	Class 3: VUS	CRC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	None	1x mut. MSH6 and 1x mut. PMS2	dMMR - VUS MSH2
19	ID_328	CRC_328	MLH1	c.1153 C>T	p.Arg385Cys	Class 3: VUS	CRC	MSH2/MSH6	NT	MSI-H / dMMR 6/6	None	1x LOH MSH2 and 1x mut. MSH2	dMMR - double somatic MSH2
20	ID_395	CRC_395	MSH2	c.668 T>C	p.Leu223Pro	Class 3: VUS	CRC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 6/6	None	1x LOH MLH1 and 1x mut. MLH1	dMMR - double somatic MLH1
21	ID_089	CRC_089	MSH6	c.2827 G>T	p.Asp943Tyr	Class 3: VUS	CRC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 6/6	None	1x LOH MLH1 and 2x mut. PMS2	dMMR - double somatic MLH1
22	ID_046	EC_046	MSH6	c.2950 A>C	p.Asp84His	Class 3: VUS	EC	PMS2	NEGATIVE	MSI-H / dMMR 4/6	1x mut. MSH6	2x mut. PMS2	dMMR - double somatic PMS2
23	ID_352 ²	CRC2_352	PMS2	c.241 G>A	p.Glu81Lys	Class 3: VUS	CRC	MSH2/MSH6	NT	MSI-H / dMMR 5/6	None	2x mut. MSH2 , 2x mut. MLH1 and 1x mut. MSH6	dMMR - double somatic MSH2
24	ID_193	CRC_193	PMS2	c.2149 G>A	p.Val171Met	Class 3: VUS	CRC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 5/6	None	2x mut. MLH1	dMMR - double somatic MLH1
25	ID_263	EC_263	MSH6	c.*85 T>A	p.?	Class 3: B	EC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 5/6	1x LOH MLH1 and 1x mut. MLH1	1x mut. MSH6	dMMR - double somatic MLH1
26	ID_202	EC_202	MSH2	c.138 C>G	p.His46Gln	Class 2: LB	EC	MSH6	NT	MSI-H / dMMR 3/6	1x mut. MSH2	2x mut. MSH6	dMMR - double somatic MSH6
27	ID_240	CRC_240	PMS2	c.233 G>A	p.Gly779Arg	Class 3: VUS	CRC	Normal	NEGATIVE	MSS / pMMR 10/6	None	None	pMMR
28	ID_352 ²	CRC1_352	PMS2	c.241 G>A	p.Glu81Lys	Class 3: VUS	CRC	Normal	NT	MSS / pMMR 13/6	None	2x mut. MLH1 and 2x mut. MSH6	pMMR
29	ID_161 ¹	EC_161	MSH6	c.4068_4071 dup	p.Lys1358Aspfs*2	Class 2: LB	EC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR 6/6	None	1x mut. MLH1	VUS benign

390

391 **Table 3.** Overview of targeted tumor sequencing results from the test group including sequenced
 392 family members. Abbreviations: ID, identification number; CRC, colorectal cancer; EC,
 393 endometrial cancer; LP, likely pathogenic; VUS, variant of uncertain clinical significance; LB,
 394 likely benign; B, benign; IHC, immunohistochemistry; MMR, DNA mismatch repair; MSI,
 395 microsatellite instability; MSI-H, high levels of microsatellite stability; MSS, microsatellite
 396 stable; dMMR, DNA mismatch repair deficient; pMMR, DNA mismatch repair proficient; LOH,
 397 loss of heterozygosity; mut., single somatic mutation; NT, not tested.

398 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

399 ¹ Participant (ID_161) developed a single endometrial cancer showing loss of MLH1/PMS2 by
 400 immunohistochemistry but carried two VUS; one in *MLH1* and one in *MSH6*

401 ² Participant (ID_352) carried a PMS2 VUS but developed two different CRCs; one with loss of
 402 MSH2/MSH6 protein expression and one with no loss of MMR protein expression (pMMR)

403

404 3.4 Determining Somatic MMR Gene Second Hit using Tumor Sequencing Data

405 Following the “two-hit” model for Lynch syndrome, a somatic second hit would be expected in
 406 the same gene as the gene carrying the germline variant. We aimed to identify the presence of a
 407 somatic MMR mutation as the second hit in the gene carrying the germline MMR VUS. For the
 408 reference group of dMMR Lynch syndrome tumors, 13 of the 16 (81.3%) harbored a detectable
 409 somatic second hit in the same MMR gene harboring the germline pathogenic variant, which

410 included single somatic mutations (6/13, 46%) and LOH (7/13, 53.8%) (**Table S1, Figure S2A**).
411 Of the 18 reference pMMR non-MMR carrier tumors, only 2/18 (11.1%) harbored a somatic
412 mutation in one of the four MMR genes, both of which were LOH events (**Table S1, Figure**
413 **S2A**). The findings from these reference tumors highlights the enrichment of somatic MMR
414 mutations as second hits in Lynch syndrome related CRCs and ECs. Similarly, in the test group,
415 for 86.7% of the cases (13/15), a second hit could be identified where the MMR VUS was
416 concordant to the IHC pattern of loss. The second hit was more commonly a single somatic
417 mutation (**Figure S2B**). Equivalent to the reference group, for cases with no MMR loss of
418 protein expression by IHC, the second hit was exclusively of LOH mutation type (**Figure S2A,**
419 **Figure S2B**).

420 For 7/9 (77.8%) tumors from the 7 VUS reclassified by ACMG/InSiGHT framework to
421 LP, a second hit was identified (**Table 3**). There were two exceptions. The first was an EC
422 diagnosed at 55-60 years from person ID_315-2 who carried the *MSH2* c.1862G>T
423 p.(Arg621Leu) variant but the tumor showed loss of MLH1/PMS2⁺ expression related to tumor
424 *MLH1* promoter methylation. The sister (ID_315) was also a carrier and developed an EC at 61-
425 65 years, which demonstrated loss of MSH2/MSH6 expression and a somatic second hit in
426 *MSH2*. The second exception was an EC diagnosed at 51-55 years from ID_156 who carried the
427 *MSH6* c.3556+5_3556+9delins variant that was MSI-H/dMMR from tumor sequencing, showed
428 solitary loss of MSH6 expression but no somatic mutation in *MSH6*, however, a CRC diagnosed
429 at 61-65 years in ID_156 also showed solitary loss of MSH6 expression with a second hit in
430 *MSH6*.

431 There were an additional 8 tumors from 7 VUS carriers that were not reclassified by
432 ACMG/InSiGHT framework, but did demonstrate a second hit (**Table 3**), including ID_176 who
433 carried the *MLH1* c.1594G>C p.(Gly532Arg) variant and developed MLH1/PMS2 deficient
434 CRC and EC, in the absence of *MLH1* methylation, where a second hit was observed in both
435 tumors. Two VUS carriers, ID_170 (*MLH1* c.-117G>T p.?) and ID_111 (*MSH6* c.1153_1155del
436 p.(Arg385del)), demonstrated MSI-H/dMMR by tumor sequencing and a second hit in their
437 respective CRCs, however, both CRCs were pMMR by IHC suggesting a false negative MMR
438 IHC result. An additional VUS carrier, ID_376 (*MSH2* exon 1-6 duplication) whose CRC
439 showed loss of *MSH2/MSH6* by IHC, MSI-H/dMMR by tumor sequencing, did not harbor a
440 second hit in the *MSH2* gene (**Table 3**).

441 There were a further 8 VUS carriers whose tumors were all MSI-H/dMMR by tumor
442 sequencing but their pattern of MMR protein loss by IHC indicated a different MMR gene was
443 defective to the one harboring the VUS (**Table 3**). Tumor sequencing revealed two somatic
444 MMR mutations (also known as “double somatics”), which were likely responsible for the
445 pattern of MMR protein loss by IHC in these 8 carriers. For two of these VUS (ID_263: *MSH6*
446 c.*85T>A and ID_202: *MSH2* c.138C>G p.(His46Gln)) a second hit was observed, however, the
447 ACMG/InSiGHT framework reclassified these variants as benign and likely benign, respectively
448 (**Table 3**).

449 The specificity of the somatic MMR mutations to the MMR gene harboring the VUS was
450 assessed. For the reference group of dMMR Lynch syndrome tumors, a somatic second hit was
451 identified in 100% of *MLH1* (n=4), in 70% of *MSH2* (n=10), in 100% of *MSH6* (n=1) and 100%
452 of *PMS2* (n=1) germline pathogenic variant carriers but somatic MMR mutations in the other
453 MMR genes were rarely observed (**Table S1**). For the reference pMMR non-Lynch syndrome
454 tumors, the presence of any MMR somatic mutation was found in only 11.1% (2/18) of the cases
455 screened (**Table S1**). In the test group, for the MMR VUS categorized as LP by the
456 ACMG/InSiGHT framework, only 3/9 (33.3%) tumors presented with ≥ 1 somatic event in the
457 gene that did not harbor the germline VUS (**Table 3, Figure 2**). For the three cases where the
458 germline VUS was classified as LB/B, a different molecular mechanism, e.g., double somatic
459 MMR mutations (n=2) or a concomitant germline variant plus somatic second hit in the same
460 gene (n=1, ID_161), is the likely cause for the observed tumor dMMR (**Table 3, Figure 2**).


Tumor	VUS	MMR IHC	MLH1	MSH2	MSH6	PMS2	ACMG/InSiGHT	MLH1 hypermeth	MSI/MMR	2 nd somatic hit	dMMR crypt/gland
CRC_326	MLH1 c.1595G>A p.(Gly532Asp)	MLH1+/PMS2	germ Y	som LOH	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_149	MSH2 exon 14-15 duplication p.?	MSH2/MSH6	germ -	som -	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_315	MSH2 c.1862G>T p.(Arg621Leu)	MSH2/MSH6	germ Y	som Mut	germ Y	som Mut	LP	Positive	MSI-H/dMMR	Present	Present
EC_315-2	MSH2 c.1862G>T p.(Arg621Leu)	MLH1/PMS2+	germ -	som -	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_008	MSH2 c.2005+3_2005+14del p.?	MSH2/MSH6	germ Y	som Mut	germ Y	som Mut	LP	Positive	MSI-H/dMMR	Present	Present
CRC_132	MSH2 c.2060T>C p.(Leu687Pro)	MSH2/MSH6	germ Y	som Mut	germ Y	som Mut	LP	Positive	MSI-H/dMMR	Present	Present
CRC_156	MSH6 c.3556+5_3556+8delins p.?	MSH6	germ -	som -	germ Y	som 2x Mut	LP	Positive	MSI-H/dMMR	Present	Present
EC_156	MSH6 c.3556+5_3556+8delins p.?	MSH6	germ -	som -	germ Y	som 2x Mut	LP	Positive	MSI-H/dMMR	Present	Present
EC_143	PMS2 c.137G>T p.(Ser46Ile)	PMS2	germ -	som -	germ -	som 2x Mut	LP	Positive	MSI-H/dMMR	Present	Present
EC_202	MSH2 c.138C>G p.(His46Gln)	MSH6	germ -	som -	germ Y	som 2x Mut	LP	Positive	MSI-H/dMMR	Present	Present
EC_161	MSH6 c.4068_4071dup p.(Lys1358Aspfs*2)	MLH1/PMS2	germ -	som -	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_263	MSH6 c.*85T>A p.?	MLH1+/PMS2	germ -	som LOH+ Mut	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_161	MLH1 c.539_541del p.(Val180del)	MLH1/PMS2	germ Y	som Mut	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_051	MLH1 c.71_85del p.(Val24_Pro28del)	MLH1/PMS2	germ Y	som LOH+ Mut	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_176	MLH1 c.1594G>C p.(Gly532Arg)	MLH1/PMS2	germ Y	som LOH	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_176	MLH1 c.1594G>C p.(Gly532Arg)	MLH1+/PMS2	germ Y	som 2x Mut	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_170	MLH1 c.-117G>T p.?	Normal	germ Y	som LOH	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_328	MLH1 c.1153C>T p.(Arg385Cys)	MSH2/MSH6	germ Y	som -	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_058	MSH2 exon 1-6 duplication p.?	MSH2/MSH6	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_138	MSH2 c.328A>C p.(Lys110Gln)	MSH2/MSH6	germ Y	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_376	MSH2 exon 1-6 duplication p.?	MSH2/MSH6	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_395	MSH2 c.668T>C p.(Leu223Pro)	MLH1/PMS2	germ -	som LOH+ Mut	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_111	MSH6 c.1153_1155del p.(Arg385del)	Normal	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_089	MSH6 c.2827G>T p.(Asp943Tyr)	MLH1/PMS2	germ -	som LOH+ 2xMut	germ -	som -	LP	Positive	MSI-H/dMMR	Present	Present
EC_046	MSH6 c.2950A>C p.(Asn984His)	PMS2	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC2_352	PMS2 c.241G>A p.(Glu81Lys)	MSH2/MSH6	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_193	PMS2 c.2149G>A p.(Val717Met)	MLH1/PMS2	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC_240	PMS2 c.2335G>A p.(Gly779Arg)	Normal	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present
CRC1_352	PMS2 c.241G>A p.(Glu81Lys)	Normal	germ -	som -	germ Y	som -	LP	Positive	MSI-H/dMMR	Present	Present

461
 462 **Figure 2.** Overview of the number and type of somatic events by the 25 germline DNA
 463 mismatch repair variants of uncertain significance screened in this study. Red highlighted text
 464 indicates duplicate entries per row. *Abbreviations:* VUS, variant of uncertain significance; germ,
 465 germline variant; som, somatic mutation; ACMG, American College of Medical Genetics and
 466 Genomics; InSiGHT, International Society for Gastrointestinal Hereditary Tumours; MMR,
 467 DNA mismatch repair; dMMR, DNA mismatch repair deficient; pMMR, DNA mismatch repair
 468 proficient; IHC, immunohistochemistry; MSI, microsatellite instability; MSI-H, high levels of
 469 microsatellite instability; MSS, microsatellite stable; LOH, loss of heterozygosity; LP, likely
 470 pathogenic; LB, likely benign; B, benign.
 471 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC
 472 ¹ Determination of the MSI/MMR status using the additive feature combination approach as
 473 previously described in Walker *et al.*, 2023

474

475 *3.5 Detection of DNA Mismatch Repair Deficient Crypts / Glands in Normal Tissue*

476 To establish the protocol, screening of normal colonic mucosa for dMMR crypts was performed
477 for three pathogenic variant carriers from the reference group with available tissue. Two crypts
478 from two different carriers demonstrated a loss of expression of the MLH1 protein which was
479 concordant with the germline pathogenic variant in *MLH1* (**Figure 3A, Table S1, Table 4**). The
480 screening did not identify a dMMR crypt in the third reference case (Ref_411) from 2x80µM
481 tissue screening, after which the tissue was depleted. In addition to finding a dMMR crypt in the
482 normal colonic mucosa of *MLH1* pathogenic variant carrier Ref_029, a dMMR crypt was
483 identified in the normal colonic mucosa of their relative (Ref_029-2) who was also a carrier of
484 the family *MLH1* pathogenic variant (**Table 4**). No dMMR crypts were identified from 3x80µM
485 tissue screening of the normal colonic mucosa from two CRC-affected people who did not carry
486 a germline MMR pathogenic variant (**Table 4**).



487
488 **Figure 3.** Detection of DNA mismatch repair deficient crypts or glands in (A) the reference and
489 (B) the test group with three cases identified each. *Abbreviations:* MMR, DNA mismatch repair;
490 dMMR, DNA mismatch repair deficient; IHC, immunohistochemistry.
491

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

#	Carrier Type	Carrier ID	Tissue	IHC	MLH1 Methylation	Gene	Variant	ACMG/InSiGHT Classification	Evaluation of Screening Assays for Potential Addition to Current Variant Classification Approaches			Amount Screened	Final Tumor Classification
									MSI-H/dMMR by Additive Feature Approach	Presence of a Somatic Second Hit	Presence of a dMMR Crypt / Gland		
1	Reference	Ref_029	CRC	MLH1/PMS2	NT	MLH1	c.17.13_17.16delTTGGT p.Phe 57 1Leufs* 29	Class 5: P	Yes	Yes	Yes	2x80µM	dMMR - LS + 2nd hit (MLH1)
2	Reference	Ref_029-2 ¹	CRC	MLH1/PMS2	NT	MLH1	c.17.13_17.16delTTGGT p.Phe 57 1Leufs* 29	Class 5: P	NA	NA	Yes	10x4µM	dMMR - LS (MLH1)
3	Reference	Ref_605	CRC	MLH1/PMS2	NT	MLH1	c.1852_1854delAAG p.Lys618del	Class 5: P	Yes	Yes	Yes	1x80µM	dMMR - LS + 2nd hit (MLH1)
4	Reference	Ref_411	CRC	MSH2/MSH6	NT	MSH2	c.1889_1892delGAAAG p.Gly630Glu*4	Class 5: P	Yes	Yes	No ²	2x80µM	dMMR - LS + 2nd hit (MSH2)
5	Reference	Ref_897 ³	CRC	Normal	NT	-	Wildtype	NA	NA	NA	No	3x80µM	pMMR - non-LS
6	Reference	Ref_972 ³	CRC	Normal	NT	-	Wildtype	NA	NA	NA	No	3x80µM	pMMR - non-LS
7	Test - Proband	ID_051	EC	MLH1/PMS2	NEGATIVE	MLH1	c.71_85del p.Val24_Pro28del	Class 3: VUS	Yes	Yes	No	10x4µM	dMMR - VUS + 2nd hit (MLH1)
8	Test - Proband	ID_161	EC	MLH1/PMS2	NEGATIVE	MLH1	c.59_54del p.Val180del	Class 3: VUS	Yes	Yes	No	3x80µM	dMMR - VUS + 2nd hit (MLH1)
9	Test - Proband	ID_176	CRC	MLH1/PMS2	NEGATIVE	MLH1	c.1594G>C p.Gly532Arg	Class 3: VUS	Yes	Yes	No	3x80µM	dMMR - VUS + 2nd hit (MLH1)
10	Test - Proband	ID_326	CRC	MLH1/PMS2	NEGATIVE	MLH1	c.1595G>A p.Gly532Asp	Class 4: LP	Yes	Yes	No ²	2x80µM	dMMR - VUS + 2nd hit (MLH1)
11	Test - Proband	ID_058	EC	MSH2/MSH6	NT	MSH2	Exon 1-6 duplication	Class 3: VUS	Yes	Yes	Yes	1x80µM	dMMR - VUS + 2nd hit (MSH2)
12	Test - Proband	ID_376	CRC	MSH2/MSH6	NT	MSH2	Exon 1-6 duplication	Class 3: VUS	Yes	No	No	3x80µM	dMMR - VUS (MSH2)
13	Test - Proband	ID_138	CRC	MSH2/MSH6	NT	MSH2	c.328A>C p.Lys110Gln	Class 3: VUS	Yes	Yes	No	1x4µM	dMMR - VUS + 2nd hit (MSH2)
14	Test - Relative	ID_315-2	EC	MLH1/PMS2 ¹	POSITIVE	MSH2	c.1862G>T p.Arg621Leu	Class 4: LP	No	No	Yes	1x80µM	dMMR - MLH1 methylation
15	Test - Proband	ID_132	CRC	MSH2/MSH6	NT	MSH2	c.2060T>C p.Leu687Pro	Class 4: LP	Yes	Yes	No ²	10x4µM	dMMR - VUS + 2nd hit (MSH2)
16	Test - Proband	ID_156	CRC	MSH6	NT	MSH6	c.3556+5_3556+8delins	Class 4: LP	Yes	Yes	Yes	10x4µM	dMMR - VUS + 2nd hit (MSH2)
17	Test - Proband	ID_046	EC	PMS2	NEGATIVE	MSH6	c.2950A>C p.Asn984His	Class 3: VUS	Yes	Yes	No	3x80µM	dMMR - double somatic (PMS2)
18	Test - Proband	ID_143	EC	PMS2	NEGATIVE	PMS2	c.337G>T p.Ser46Ile	Class 4: LP	Yes	Yes	Failed test	3x80µM	dMMR - VUS + 2nd hit (PMS2)

492
493 **Table 4.** Overview of normal tissue screening for DNA mismatch repair deficient crypts and
494 glands in the reference and test groups. Abbreviations: ID, identification number; CRC,
495 colorectal cancer; EC, endometrial cancer; IHC, immunohistochemistry; P, pathogenic; LP,
496 likely pathogenic; VUS, variant of uncertain significance; LB, likely benign; MMR, DNA
497 mismatch repair; dMMR, DNA mismatch repair deficiency; pMMR, DNA mismatch repair
498 proficiency; MSI-H, high levels of microsatellite stability; MSS, microsatellite stable; NA, not
499 applicable; NT, not tested; LS, Lynch syndrome; MLH1me, *MLH1* gene promoter
500 hypermethylation.

501 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

502 ¹ Relative of Ref_029 who is also carrier of the family *MLH1* pathogenic variant was identified
503 to have a dMMR crypt in normal colonic mucosa, but their CRC did not undergo tumor
504 sequencing

505 ² Block was depleted after screening of 2x80µM of normal tissue

506 ³ This sample did not undergo next-generation sequencing

507 ⁴ Only received slides

508
509 For 12/25 (48%) of MMR VUS carriers, normal tissue specimens (6x normal colonic and 6x
510 normal endometrial tissue) were available for dMMR crypt/gland screening. A single case
511 (ID_143) was a technical failure for PMS2 IHC staining due to poor tissue fixation of the normal
512 tissue. In 7/11 (63.6%) of the remaining cases, normal tissue blocks were available for screening
513 while for 4/11 (36.4%) of the cases, only 4µM normal tissue sections on slides were available for
514 screening. A total of three carriers (27.3%) had a dMMR crypt/gland identified out of 11 carriers
515 tested (**Table 4, Figure 3B**). Two of these were in normal endometrium tissue with the
516 remaining dMMR crypt identified in normal colonic mucosa. Out of four cases that were
517 reclassified as likely pathogenic based on the ACMG/InSiGHT criteria and where normal tissue
518 was available for testing, 2/4 (ID_315: *MSH2* c.1862G>T p.(Arg621Leu) and ID_156: *MSH6*
519 c.3556+5_3556+8delins) had a dMMR gland and dMMR crypt identified, respectively (**Table**
520 **4**). A dMMR endometrial gland was identified in the carrier of *MSH2* exon 1-6 duplication
521 (ID_058), where the tumor also demonstrated MSI-H/dMMR by tumor sequencing, a somatic
522 second hit in *MSH2* and showed loss of MSH2/MSH6 expression by IHC, however, the

523 ACMG/InSiGHT framework did not result in a reclassification of the VUS (**Table 4**). The
524 pathogenic criterion (PVS1) from the ACMG guidelines could not be applied for a predicted loss
525 of function as the location of the partial gene duplication was unknown, making it uncertain if
526 nonsense mediated mRNA decay would take place [53].

527

528 **4. Discussion**

529 In this study, tumor and non-malignant tissue features associated with germline pathogenic
530 MMR variant carriers were investigated to determine their utility to aid MMR variant
531 classification. Our findings from the investigation of 28 tumors from 25 VUS carriers showed
532 that tumor MSI-H/dMMR status, determined by tumor sequencing and an additive feature
533 combination approach [22], agreed with variant LP/P classification (**Figure 4**). We found MSI-
534 H/dMMR status by tumor sequencing was 100% concordant with dMMR status by IHC in both
535 our reference group of dMMR Lynch syndrome tumors (**Figure S3**) and in the tumors from 7
536 VUS carriers that were reclassified to LP by the ACMG/InSiGHT framework (**Table 3**), while
537 the reference group of pMMR non-MMR carrier tumors were MSS/pMMR by tumor sequencing
538 (**Figure S3**). Furthermore, the identification of a somatic second hit was also consistent with
539 variant LP/P classification. A second hit was observed in 81.3% of the reference group of
540 dMMR Lynch syndrome tumors (**Figure S3**) and 77.8% of the tumors from VUS reclassified to
541 LP (**Table 3**) in contrast to only 11.1% of tumors from the reference group of pMMR non-MMR
542 carriers having a somatic MMR mutation (**Figure S3**). In light of these findings, a further 7
543 VUS, that could not be reclassified by the ACMG/InSiGHT framework demonstrated tumors
544 with MSI-H/dMMR and a second hit, suggesting that these 7 VUS could be upgraded to an LP
545 classification (**Table 3**). Screening for the presence of a dMMR crypt/gland also showed
546 potential for clinical utility for LP/P variant classification. In addition to the three known
547 pathogenic variant carriers from the reference group, three additional VUS carriers were found to
548 have a dMMR crypt/gland, where in two of these the ACMG/InSiGHT framework reclassified
549 the VUS to LP (**Table 4**). The remaining VUS case with a dMMR endometrial gland was
550 identified in the carrier of *MSH2* exon 1-6 duplication (ID_058), and together with the tumor
551 also demonstrating MSI-H/dMMR by tumor sequencing and a somatic second hit, is supportive
552 of an LP classification for this variant (**Table 4**). Therefore, the application of tumor sequencing
553 for MSI/dMMR status and presence of a second hit together with testing for dMMR
554 crypts/glands is likely to improve MMR variant classification.

555 The use of tumor characteristics to support MMR variant classification continues to
556 evolve. MMR IHC and testing for somatic *BRAF* p.V600E mutation and/or *MLH1* promoter
557 methylation are commonly used to identify or exclude CRCs and ECs for germline MMR gene
558 testing and thus these features have been incorporated into existing MMR VUS classification
559 approaches [15,16]. The investigation of somatic features derived from tumor next generation
560 sequencing to support MMR variant classification has important potential. The determination of
561 MSI/dMMR by NGS has resulted in the development of multiple accurate MSI calling tools [44–
562 47], where our previous study compared these tools and other dMMR-related tumor features to

579 **Figure 4.** Sunburst diagram displaying the prevalence of the three Lynch syndrome associated
580 features in the test group. The diagram incorporates the tumor sequencing and dMMR
581 crypt/gland screening for determining pathogenicity against the ACMG/InSiGHT framework for
582 MMR VUS included in the test group. *Abbreviations:* MMR, DNA mismatch repair; dMMR,
583 DNA mismatch repair deficient; pMMR, DNA mismatch repair proficient; MSI, microsatellite
584 instability; MSI-H, high levels of microsatellite instability; MSS, microsatellite stable; VUS,
585 variant of uncertain clinical significance; LP, likely pathogenic; LB, likely benign; B, benign.
586

587 A recent study has investigated the benefit of identifying the somatic second hit for
588 variant classification. Scott *et al.* (2022) showed that somatic second hit mutations in *MSH2* were
589 significantly more common in tumors from *MSH2* missense variant carriers that had multiplexed
590 analysis of variant effect (MAVE) data, indicating, the germline variant was functionally
591 disruptive (i.e., pathogenic variant) when compared with tumors from *MSH2* missense variant
592 carriers with MAVE scores indicating the germline variant was functionally normal (i.e., benign
593 variant) [53]. This supports the observations from this study where a somatic second hit was
594 more prevalent in both known pathogenic variant carriers as well as VUS that were reclassified
595 to LP but rare in pMMR tumors.

596 A study performed by Shirts *et al.* (2018) demonstrated that tumor mutations in the MMR
597 genes can support both pathogenic and benign variant classification by identifying somatic driver
598 mutations compared with passenger mutations in patients with unexplained dMMR (i.e.,
599 suspected Lynch syndrome or Lynch-like syndrome) [54]. Furthermore, the authors propose that
600 the cumulative evidence from independent mutations identified from sequencing unexplained
601 dMMR tumors will ultimately classify more germline MMR gene variants. Given the rarity of
602 some individual constitutional MMR gene variants, the observation of these same variants as
603 somatic mutations in multiple dMMR tumors may expedite their classification. The detection of
604 a somatic second hit, as we have shown in this study, as well as the work described by Shirts and
605 colleagues, demonstrates that the detection of somatic MMR mutations in tumors, with
606 confirmed MSI-H/dMMR status, can support MMR variant classification and warrants
607 modifications of the ACMG/InSiGHT MMR variant classification guidelines to incorporate the
608 characteristics of somatic mutations from tumor sequencing data.

609 An important finding from this study was the identification of double somatic MMR
610 mutations in an MMR gene that was not the gene harboring the VUS. Double somatic MMR
611 mutations are a recognized cause of somatic biallelic MMR gene inactivation that can lead to
612 tumor MSI-H/dMMR phenotype [23,33,55,56]. The additional information provided by the
613 pattern of MMR protein loss by IHC was supportive that the MSI-H/dMMR tumor phenotype
614 was caused by two somatic MMR mutations and not related to the VUS. Two of these VUS were
615 reclassified as LB/B, supporting the somatic mutation data but in MSI-H-dMMR tumors (**Table**
616 **3**). A caveat to these findings was the presence of two somatic *MSH2* mutations in the CRC from
617 person ID_138 carrying the *MSH2* c.328A>C p.(Lys110Gln) VUS (**Table 3**). One of these two
618 somatic *MSH2* mutations may represent the second hit to the germline VUS, however, the two

619 somatic *MSH2* mutations may represent somatic biallelic inactivation (**Table 3**). Of interest, the
620 MAVE data for this *MSH2* missense VUS suggests it is likely benign [57] supporting a “double
621 somatic” rather than a germline cause of MSI-H/dMMR for this tumor. Consideration of the
622 number of somatic MMR mutations identified together with MMR IHC findings will help to
623 interpret tumor sequencing data for MMR variant classification.

624 There were 4 tumors from 4 carriers where no loss of MMR protein expression was
625 observed by IHC (**Table 3**). Two tumors (CRC_240 and CRC1_352) were MSS/pMMR by
626 tumor sequencing supporting IHC result. The other two tumors (CRC_170 and CRC_111) were
627 MSI-H/dMMR by NGS and showed a somatic second hit in the gene with the VUS (both LOH
628 events), which may suggest false negative MMR IHC result.

629 The presence of a dMMR crypt or gland is a strong predictor for a variant being pathogenic
630 given its specificity for Lynch syndrome [24–29]. In this study, a single endometrial gland
631 showed loss of *MSH2* expression in the patient harboring the *MSH2* exon 1-6 duplication
632 (ID_058) which would support this variant being pathogenic (**Table 4**). The absence of
633 detectable dMMR crypts/glands does not conversely support a LB/B classification and could
634 simply reflect insufficient tissue was screened. The exact prevalence of dMMR crypts/glands
635 across normal tissues still needs to be assessed in ancillary studies, however, Kloor *et al.* (2012)
636 have indicated the detection of dMMR crypts in 1cm² of colonic mucosa in Lynch syndrome
637 patients [24]. The feasibility in terms of the amount of biopsy needed to get at least 1cm² and
638 cost-effectiveness of screening for dMMR crypts/glands in clinical setting needs to be
639 determined but may offer an alternate approach to reclassify an MMR variant particularly when
640 evidence from the existing ACMG/InSiGHT framework is insufficient.

641 A strength of the study was the comparison of data from the existing gold standard MMR
642 variant classification framework to the application of novel features, particularly those derived
643 from NGS which is increasing in clinical diagnostics. The detection of MSI-H/dMMR and a
644 second hit from tumor sequencing is unlikely to be influenced by the type of variant. Further
645 studies are needed to determine if the detection of dMMR crypts/glands is likely to be influenced
646 by variant type. Furthermore, the implementation of screening for dMMR crypts or glands would
647 be based on established MMR protein antibodies and immunohistochemical protocols and,
648 therefore, potentially more applicable to a broader spectrum of laboratories once the tissue is
649 available. A further demonstrated strength by this study was the ability to detect dMMR
650 crypts/glands on FFPE archival tissue that was up to 20 years old (e.g., reference group tissue)
651 with only a single case (ID_143) failing testing.

652 This study has several limitations. An important caveat for interpreting the presence of a
653 dMMR crypt/gland for VUS classification is the concept that another undetected pathogenic
654 variant underlies the dMMR crypt/gland rather than the VUS. Therefore, interpretation of the
655 presence of a dMMR crypt/gland should be considered alone but together with additional
656 information used to classify MMR variants. Another limitation of the study was access to normal
657 tissue as we were only able to acquire normal tissue specimen for half of the cases (48%, 12/25).
658 Broader recognition that screening for dMMR crypts/glands has utility for variant classification

659 may encourage better collection and access to normal tissue. A single Lynch syndrome tumor
660 phenocopy was identified in the case of ID_315-2, where the tumor was positive for *MLH1*
661 methylation despite the person carrying the *MSH2* LP variant. Although phenocopies in Lynch
662 syndrome are rare, the interpretation of tumor data for MMR variant classification needs detailed
663 examination. Lastly, it is possible that somatic second hits were missed in some of the tumors.
664 This was evident for the Lynch syndrome reference tumors where a second hit was identified in
665 only 81.3% of sequenced tumors. Challenges in identifying more complex/cryptic variants from
666 capture-based sequencing data or the possibility the second hit is an intronic variant not targeted
667 by the capture may explain the missing second hits. These challenges may underlie second hit
668 detection in the VUS cases tested in this study where, for example, the EC from person ID_156
669 who carried the *MSH6* c.3556+5_3556+9delins variant and CRC from person ID_376 who
670 carried the *MSH2* exon 1-6 duplication did not identify a second hit despite the other cumulative
671 evidence suggesting these variants are likely pathogenic. Lastly, complementary data could be
672 gained from functional assays such as RT-PCR or minigene constructs to provide further
673 functional evidence to support variant classification.

674

675 **5. Conclusions**

676 This study evaluated novel approaches to classify MMR variants, providing support for their
677 potential incorporation into current variant classification guidelines as additional independent
678 lines of evidence to aid MMR variant classification. Currently, somatic MMR mutation data is
679 not used in MMR gene variant classification frameworks, but this study and other studies
680 provide support for information gained from sequencing of dMMR tumors. Although the
681 presence of a somatic second hit was concordant with LP/P variant classification, the knowledge
682 that the presence of two somatic MMR gene mutations (double somatics) can also result in MSI-
683 H/dMMR tumor phenotype needs to be acknowledged when interpreting tumor sequencing
684 findings for variant classification. Furthermore, somatic MMR mutation data from tumor
685 sequencing needs to be considered in conjunction with confirmation the tumor is MSI-H/dMMR.
686 The presence of a dMMR crypt/gland in normal colonic or endometrial tissue represents a novel
687 approach to guide LP/P MMR variant classification. The identification of germline MMR VUS
688 prior to surgery may facilitate preservation of more normal tissue for testing but the application
689 of dMMR crypt/gland detection using normal colonic biopsies from colonoscopy in unaffected
690 VUS carriers needs further investigation. Our findings have shown the potential utility of tumor
691 sequencing to determine both MSI/MMR status and presence of single point mutation/LOH as a
692 somatic second hit, and with assessment of normal tissue for the presence of dMMR
693 crypts/glands for improving MMR variant classification and warrants consideration for inclusion
694 in the ACMG/InSiGHT framework.

695

696 **Supplementary Materials:** Figure S1: Bar plot presenting the feature count for targeted panel
697 sequenced (A) reference and (B) test groups to determine the DNA mismatch repair status in
698 next-generation sequencing screened tumors after applying the additive feature combination

699 approach; Figure S2: Pie charts presenting the proportions of the presence of a somatic second
700 hit and by which mutation type for (A) the reference and (B) the test groups; Figure S3:
701 Flowchart displaying the prevalence of the three Lynch syndrome associated features in the
702 reference group; Table S1: Overview of tumors included in the reference group.

703
704 **Author Contributions:** RW, IMW and DDB contributed to the conception and design of the
705 study. IMW, DDB, MAJ, FAM, SJ, RA, JB, MB, AC, EE, MG, AG, MTH, EI, JK, JM, HM,
706 CN, NP, AR, AS and RS contributed to the recruitment of study participants. RW, MC, JEJ, JC
707 and SGP contributed to sample preparation and quality control. RW, MC, JEJ, KM, PG and
708 DDB contributed to the data analysis. RW, MC, JEJ, KM, PG and DDB contributed to the
709 interpretation of findings. RW and JMC generated the pedigrees using Python. CR, RKP and MC
710 reviewed IHC findings. RW and DDB drafted and substantively revised the manuscript. RW,
711 IMW and DDB contributed to the overall supervision of the project. All authors have read and
712 agreed to the published version of the manuscript.

713
714 **Funding:** This project was funded by a National Health and Medical Research Council of
715 Australia (NHMRC) project grant GNT1125269 (PI- Daniel Buchanan). DDB is supported by an
716 NHMRC Investigator grant (GNT1194896) and University of Melbourne Dame Kate Campbell
717 Fellowship. RW is supported by the Margaret and Irene Stewardson Fund Scholarship and by the
718 Melbourne Research Scholarship. PG is supported by the University of Melbourne Research
719 Scholarship. MAJ is supported by an NHMRC Investigator grant (GNT1195099). The Colon
720 Cancer Family Registry (CCFR, www.coloncfr.org) is supported in part by funding from the
721 National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551).
722 Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and
723 End Results (SEER) Program and the following U.S. state cancer registries: AZ, CO, MN, NC,
724 NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada).

725
726 **Institutional Review Board Statement:** The study was conducted in accordance with the
727 Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee)
728 of The University of Melbourne (protocol code HREC#1750748, approval date: 30th of July
729 2018).

730
731 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the
732 study.

733
734 **Data Availability Statement:** The original contributions presented in the study are included in
735 the article/supplementary files, further inquiries can be directed to the corresponding author.

736
737 **Acknowledgments:** The authors thank members of the Colorectal Oncogenomics Group and
738 members from the Genomic Medicine and Family Cancer Clinic for their support of this

739 manuscript. We thank the participants and staff from the ANGELS study and from the
740 Australasian site of the Colon Cancer Family Registry (ACCFR), in particular Maggie
741 Angelakos, Samantha Fox, and Allyson Templeton for their support of this manuscript. The
742 authors thank the Australian Genome Research Facility for their collaboration on this project.
743 The CCFR graciously thanks the generous contributions of their 42,505 study participants,
744 dedication of study staff, and the financial support from the U.S. National Cancer Institute,
745 without which this important registry would not exist. The content of this manuscript does not
746 necessarily reflect the views or policies of the NIH or any of the collaborating centers in the
747 CCFR, nor does mention of trade names, commercial products, or organizations imply
748 endorsement by the US Government, any cancer registry, or the CCFR.

749

750 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the
751 design of the study; in the collection, analyses, or interpretation of data; in the writing of the
752 manuscript; or in the decision to publish the results.

753

754 **References**

- 755 1. Win, A.K.; Jenkins, M.A.; Dowty, J.G.; Antoniou, A.C.; Lee, A.; Giles, G.G.; Buchanan,
756 D.D.; Clendenning, M.; Rosty, C.; Ahnen, D.J.; et al. Prevalence and Penetrance of Major Genes
757 and Polygenes for Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev* **2017**, *26*, 404–412,
758 doi:10.1158/1055-9965.EPI-16-0693.
- 759 2. Buchanan, D.D.; Clendenning, M.; Rosty, C.; Eriksen, S.V.; Walsh, M.D.; Walters, R.J.;
760 Thibodeau, S.N.; Stewart, J.; Preston, S.; Win, A.K.; et al. Tumour Testing to Identify Lynch
761 Syndrome in Two Australian Colorectal Cancer Cohorts. *J Gastroenterol Hepatol* **2017**, *32*,
762 427–438, doi:10.1111/jgh.13468.
- 763 3. Buchanan, D.D.; Rosty, C.; Clendenning, M.; Spurdle, A.B.; Win, A.K. Clinical
764 Problems of Colorectal Cancer and Endometrial Cancer Cases with Unknown Cause of Tumor
765 Mismatch Repair Deficiency (Suspected Lynch Syndrome). *Appl Clin Genet* **2014**, *7*, 183–193,
766 doi:10.2147/TACG.S48625.
- 767 4. Moreira, L.; Balaguer, F.; Lindor, N.; de la Chapelle, A.; Hampel, H.; Aaltonen, L.A.;
768 Hopper, J.L.; Le Marchand, L.; Gallinger, S.; Newcomb, P.A.; et al. Identification of Lynch
769 Syndrome among Patients with Colorectal Cancer. *JAMA* **2012**, *308*, 1555–1565,
770 doi:10.1001/jama.2012.13088.
- 771 5. Seppälä, T.T.; Burkhart, R.A.; Katona, B.W. Hereditary Colorectal, Gastric, and
772 Pancreatic Cancer: Comprehensive Review. *BJS Open* **2023**, *7*, zrad023,
773 doi:10.1093/bjsopen/zrad023.
- 774 6. Lynch, H.T.; Lynch, P.M.; Lanspa, S.J.; Snyder, C.L.; Lynch, J.F.; Boland, C.R. Review
775 of the Lynch Syndrome: History, Molecular Genetics, Screening, Differential Diagnosis, and
776 Medicolegal Ramifications. *Clin Genet* **2009**, *76*, 1–18, doi:10.1111/j.1399-0004.2009.01230.x.
- 777 7. Ligtenberg, M.J.; Kuiper, R.P.; Chan, T.L.; Goossens, M.; Hebeda, K.M.; Voorendt, M.;
778 Lee, T.Y.; Bodmer, D.; Hoenselaar, E.; Hendriks-Cornelissen, S.J.; et al. Heritable Somatic
779 Methylation and Inactivation of MSH2 in Families with Lynch Syndrome Due to Deletion of the
780 3' Exons of TACSTD1. *Nat Genet* **2009**, *41*, 112–117, doi:10.1038/ng.283.
- 781 8. Moller, P. The Prospective Lynch Syndrome Database Reports Enable Evidence-Based
782 Personal Precision Health Care. *Hered Cancer Clin Pract* **2020**, doi:10.1186/s13053-020-0138-
783 0.
- 784 9. Dowty, J.G.; Win, A.K.; Buchanan, D.D.; Lindor, N.M.; Macrae, F.A.; Clendenning, M.;
785 Antill, Y.C.; Thibodeau, S.N.; Casey, G.; Gallinger, S.; et al. Cancer Risks for MLH1 and MSH2
786 Mutation Carriers. *Hum Mutat* **2013**, *34*, 490–497, doi:10.1002/humu.22262.
- 787 10. Møller, P.; Seppälä, T.T.; Bernstein, I.; Holinski-Feder, E.; Sala, P.; Gareth Evans, D.;
788 Lindblom, A.; Macrae, F.; Blanco, I.; Sijmons, R.H.; et al. Cancer Risk and Survival in
789 Path_MMR Carriers by Gene and Gender up to 75 Years of Age: A Report from the Prospective
790 Lynch Syndrome Database. *Gut* **2018**, *67*, 1306–1316, doi:10.1136/gutjnl-2017-314057.
- 791 11. Vasen, H.F.A.; Möslein, G.; Alonso, A.; Bernstein, I.; Bertario, L.; Blanco, I.; Burn, J.;
792 Capella, G.; Engel, C.; Frayling, I.; et al. Guidelines for the Clinical Management of Lynch

- 793 Syndrome (Hereditary Non-polyposis Cancer). *J Med Genet* **2007**, *44*, 353–362,
794 doi:10.1136/jmg.2007.048991.
- 795 12. Rubenstein, J.H.; Enns, R.; Heidelbaugh, J.; Barkun, A.; Adams, M.A.; Dorn, S.D.;
796 Dudley-Brown, S.L.; Flamm, S.L.; Gellad, Z.F.; Gruss, C.B.; et al. American
797 Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch
798 Syndrome. *Gastroenterology* **2015**, *149*, 777–782, doi:10.1053/j.gastro.2015.07.036.
- 799 13. Adam, F.; Fluri, M.; Scherz, A.; Rabaglio, M. Occurrence of Variants of Unknown
800 Clinical Significance in Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome
801 and Lynch Syndrome: A Literature Review and Analytical Observational Retrospective Cohort
802 Study. *BMC Med Genomics* **2023**, *16*, 7, doi:10.1186/s12920-023-01437-7.
- 803 14. Vasen, H.F.A.; Blanco, I.; Aktan-Collan, K.; Gopie, J.P.; Alonso, A.; Aretz, S.;
804 Bernstein, I.; Bertario, L.; Burn, J.; Capella, G.; et al. Revised Guidelines for the Clinical
805 Management of Lynch Syndrome (HNPCC): Recommendations by a Group of European
806 Experts. *Gut* **2013**, *62*, 812–823, doi:10.1136/gutjnl-2012-304356.
- 807 15. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.;
808 Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of
809 Sequence Variants: A Joint Consensus Recommendation of the American College of Medical
810 Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **2015**, *17*, 405–
811 424, doi:10.1038/gim.2015.30.
- 812 16. Thompson, B.A.; Goldgar, D.E.; Paterson, C.; Clendenning, M.; Walters, R.; Arnold, S.;
813 Parsons, M.T.; Walsh, M.D.; Gallinger, S.; Haile, R.W.; et al. A Multifactorial Likelihood Model
814 for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence
815 Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry.
816 *Hum Mutat* **2013**, *34*, 200–209, doi:10.1002/humu.22213.
- 817 17. Baretta, M.; Le, D.T. DNA Mismatch Repair in Cancer. *Pharmacol Ther* **2018**, *189*, 45–
818 62, doi:10.1016/j.pharmthera.2018.04.004.
- 819 18. Chen, M.-L.; Chen, J.-Y.; Hu, J.; Chen, Q.; Yu, L.-X.; Liu, B.-R.; Qian, X.-P.; Yang, M.
820 Comparison of Microsatellite Status Detection Methods in Colorectal Carcinoma. *Int J Clin Exp*
821 *Pathol* **2018**, *11*, 1431–1438.
- 822 19. Wang, Y.; Shi, C.; Eisenberg, R.; Vnencak-Jones, C.L. Differences in Microsatellite
823 Instability Profiles between Endometrioid and Colorectal Cancers. *J Mol Diagn* **2017**, *19*, 57–64,
824 doi:10.1016/j.jmoldx.2016.07.008.
- 825 20. Knudson, A.G. Mutation and Cancer: Statistical Study of Retinoblastoma. *Proc Natl*
826 *Acad Sci U S A* **1971**, *68*, 820–823.
- 827 21. Hill, B.L.; Graf, R.P.; Shah, K.; Danziger, N.; Lin, D.I.; Quintanilha, J.; Li, G.;
828 Haberberger, J.; Ross, J.S.; Santin, A.D.; et al. Mismatch Repair Deficiency, next-Generation
829 Sequencing-Based Microsatellite Instability, and Tumor Mutational Burden as Predictive
830 Biomarkers for Immune Checkpoint Inhibitor Effectiveness in Frontline Treatment of Advanced
831 Stage Endometrial Cancer. *Int J Gynecol Cancer* **2023**, ijgc–2022–004026, doi:10.1136/ijgc-
832 2022-004026.

- 833 22. Walker, R.; Georgeson, P.; Mahmood, K.; Joo, J.E.; Makalic, E.; Clendenning, M.;
834 Como, J.; Preston, S.; Joseland, S.; Pope, B.J.; et al. Evaluating Multiple Next-Generation
835 Sequencing–Derived Tumor Features to Accurately Predict DNA Mismatch Repair Status. *The*
836 *Journal of Molecular Diagnostics* **2023**, *25*, 94–109, doi:10.1016/j.jmoldx.2022.10.003.
- 837 23. Haraldsdottir, S.; Hampel, H.; Tomsic, J.; Frankel, W.L.; Pearlman, R.; de la Chapelle,
838 A.; Pritchard, C.C. Colon and Endometrial Cancers with Mismatch Repair Deficiency Can Arise
839 from Somatic, Rather than Germline, Mutations. *Gastroenterology* **2014**, *147*, 1308–1316.e1,
840 doi:10.1053/j.gastro.2014.08.041.
- 841 24. Kloor, M.; Huth, C.; Voigt, A.Y.; Benner, A.; Schirmacher, P.; von Knebel Doeberitz,
842 M.; Bläker, H. Prevalence of Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome: A
843 Pathological Study. *Lancet Oncol* **2012**, *13*, 598–606, doi:10.1016/S1470-2045(12)70109-2.
- 844 25. Shia, J.; Stadler, Z.K.; Weiser, M.R.; Vakiani, E.; Mendelsohn, R.; Markowitz, A.J.;
845 Shike, M.; Boland, C.R.; Klimstra, D.S. Mismatch Repair Deficient-Crypts in Non-Neoplastic
846 Colonic Mucosa in Lynch Syndrome: Insights from an Illustrative Case. *Familial Cancer* **2015**,
847 *14*, 61–68, doi:10.1007/s10689-014-9751-2.
- 848 26. Staffa, L.; Echterdiek, F.; Nelius, N.; Benner, A.; Werft, W.; Lahrmann, B.; Grabe, N.;
849 Schneider, M.; Tariverdian, M.; von Knebel Doeberitz, M.; et al. Mismatch Repair-Deficient
850 Crypt Foci in Lynch Syndrome--Molecular Alterations and Association with Clinical
851 Parameters. *PLoS One* **2015**, *10*, e0121980, doi:10.1371/journal.pone.0121980.
- 852 27. Pai, R.K.; Dudley, B.; Karloski, E.; Brand, R.E.; O’Callaghan, N.; Rosty, C.; Buchanan,
853 D.D.; Jenkins, M.A.; Thibodeau, S.N.; French, A.J.; et al. DNA Mismatch Repair Protein
854 Deficient Non-Neoplastic Colonic Crypts: A Novel Indicator of Lynch Syndrome. *Mod Pathol*
855 **2018**, *31*, 1608–1618, doi:10.1038/s41379-018-0079-6.
- 856 28. Lof, P.; Lok, C. a. R.; Snaebjornsson, P.; McCluggage, W.G.; Dorpe, J.V.; Tummers, P.;
857 Vijver, K.V. de EP563 Mismatch Repair Deficiency Glands in Normal Endometrial Tissue as a
858 Predictor of Endometrial Carcinoma in Patients with Lynch Syndrome. *International Journal of*
859 *Gynecologic Cancer* **2019**, *29*, doi:10.1136/ijgc-2019-ESGO.620.
- 860 29. Wong, S.; Hui, P.; Buza, N. Frequent Loss of Mutation-Specific Mismatch Repair Protein
861 Expression in Nonneoplastic Endometrium of Lynch Syndrome Patients. *Modern Pathology*
862 **2020**, *33*, 1172–1181, doi:10.1038/s41379-020-0455-x.
- 863 30. Yurgelun, M.B.; Hampel, H. Recent Advances in Lynch Syndrome: Diagnosis,
864 Treatment, and Cancer Prevention. *American Society of Clinical Oncology Educational Book*
865 **2018**, 101–109, doi:10.1200/EDBK_208341.
- 866 31. Christakis, A.G.; Papke, D.J.; Nowak, J.A.; Yurgelun, M.B.; Agoston, A.T.; Lindeman,
867 N.I.; MacConaill, L.E.; Sholl, L.M.; Dong, F. Targeted Cancer Next-Generation Sequencing as a
868 Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper
869 Gastrointestinal Tract Cancers. *Cancer Epidemiology, Biomarkers & Prevention* **2019**, *28*, 1246–
870 1251, doi:10.1158/1055-9965.EPI-18-1250.
- 871 32. Georgeson, P.; Pope, B.J.; Rosty, C.; Clendenning, M.; Mahmood, K.; Joo, J.E.; Walker,
872 R.; Hutchinson, R.A.; Preston, S.; Como, J.; et al. Evaluating the Utility of Tumour Mutational

- 873 Signatures for Identifying Hereditary Colorectal Cancer and Polyposis Syndrome Carriers. *Gut*
874 **2021**, *70*, 2138–2149, doi:10.1136/gutjnl-2019-320462.
- 875 33. Walker, R.; Mahmood, K.; Joo, J.E.; Clendenning, M.; Georgeson, P.; Como, J.;
876 Joseland, S.; Preston, S.G.; Antill, Y.; Austin, R.; et al. A Tumor Focused Approach to
877 Resolving the Etiology of DNA Mismatch Repair Deficient Tumors Classified as Suspected
878 Lynch Syndrome. *Journal of Translational Medicine* **2023**, *21*, 282, doi:10.1186/s12967-023-
879 04143-1.
- 880 34. Buchanan, D.D.; Tan, Y.Y.; Walsh, M.D.; Clendenning, M.; Metcalf, A.M.; Ferguson,
881 K.; Arnold, S.T.; Thompson, B.A.; Lose, F.A.; Parsons, M.T.; et al. Tumor Mismatch Repair
882 Immunohistochemistry and DNA MLH1 Methylation Testing of Patients with Endometrial
883 Cancer Diagnosed at Age Younger than 60 Years Optimizes Triage for Population-Level
884 Germline Mismatch Repair Gene Mutation Testing. *J Clin Oncol* **2014**, *32*, 90–100,
885 doi:10.1200/JCO.2013.51.2129.
- 886 35. Jenkins, M.A.; Win, A.K.; Templeton, A.S.; Angelakos, M.S.; Buchanan, D.D.;
887 Cotterchio, M.; Figueiredo, J.C.; Thibodeau, S.N.; Baron, J.A.; Potter, J.D.; et al. Cohort Profile:
888 The Colon Cancer Family Registry Cohort (CCFRC). *Int J Epidemiol* **2018**, *47*, 387–388i,
889 doi:10.1093/ije/dyy006.
- 890 36. Newcomb, P.A.; Baron, J.; Cotterchio, M.; Gallinger, S.; Grove, J.; Haile, R.; Hall, D.;
891 Hopper, J.L.; Jass, J.; Le Marchand, L.; et al. Colon Cancer Family Registry: An International
892 Resource for Studies of the Genetic Epidemiology of Colon Cancer. *Cancer Epidemiol*
893 *Biomarkers Prev* **2007**, *16*, 2331–2343, doi:10.1158/1055-9965.EPI-07-0648.
- 894 37. Wojdacz, T.K.; Dobrovic, A. Methylation-Sensitive High Resolution Melting (MS-
895 HRM): A New Approach for Sensitive and High-Throughput Assessment of Methylation.
896 *Nucleic acids research* **2007**, *35*, doi:10.1093/nar/gkm013.
- 897 38. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A Flexible Trimmer for Illumina
898 Sequence Data. *Bioinformatics* **2014**, *30*, 2114–2120, doi:10.1093/bioinformatics/btu170.
- 899 39. Benjamin, D.; Sato, T.; Cibulskis, K.; Getz, G.; Stewart, C.; Lichtenstein, L. Calling
900 Somatic SNVs and Indels with Mutect 2019.
- 901 40. Saunders, C.T.; Wong, W.S.W.; Swamy, S.; Becq, J.; Murray, L.J.; Cheetham, R.K.
902 Strelka: Accurate Somatic Small-Variant Calling from Sequenced Tumor–Normal Sample Pairs.
903 *Bioinformatics* **2012**, *28*, 1811–1817, doi:10.1093/bioinformatics/bts271.
- 904 41. Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis,
905 H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The Catalogue Of Somatic Mutations
906 In Cancer. *Nucleic Acids Res* **2019**, *47*, D941–D947, doi:10.1093/nar/gky1015.
- 907 42. Kopanos, C.; Tsiolkas, V.; Kouris, A.; Chapple, C.E.; Albarca Aguilera, M.; Meyer, R.;
908 Massouras, A. VarSome: The Human Genomic Variant Search Engine. *Bioinformatics* **2019**, *35*,
909 1978–1980, doi:10.1093/bioinformatics/bty897.
- 910 43. Robinson, J.T.; Thorvaldsdóttir, H.; Winckler, W.; Guttman, M.; Lander, E.S.; Getz, G.;
911 Mesirov, J.P. Integrative Genomics Viewer. *Nat Biotechnol* **2011**, *29*, 24–26,
912 doi:10.1038/nbt.1754.

- 913 44. Maruvka, Y.E.; Mouw, K.W.; Karlic, R.; Parasuraman, P.; Kamburov, A.; Polak, P.;
914 Haradhvala, N.J.; Hess, J.M.; Rheinbay, E.; Brody, Y.; et al. Analysis of Somatic Microsatellite
915 Indels Identifies Driver Events in Human Tumors. *Nat Biotechnol* **2017**, *35*, 951–959,
916 doi:10.1038/nbt.3966.
- 917 45. Kautto, E.A.; Bonneville, R.; Miya, J.; Yu, L.; Krook, M.A.; Reeser, J.W.;
918 Roychowdhury, S. Performance Evaluation for Rapid Detection of Pan-Cancer Microsatellite
919 Instability with MANTIS. *Oncotarget* **2017**, *8*, 7452–7463, doi:10.18632/oncotarget.13918.
- 920 46. Ni Huang, M.; McPherson, J.R.; Cutcutache, I.; Teh, B.T.; Tan, P.; Rozen, S.G. MSIseq:
921 Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. *Sci Rep*
922 **2015**, *5*, 13321, doi:10.1038/srep13321.
- 923 47. Niu, B.; Ye, K.; Zhang, Q.; Lu, C.; Xie, M.; McLellan, M.D.; Wendl, M.C.; Ding, L.
924 MSIsensor: Microsatellite Instability Detection Using Paired Tumor-Normal Sequence Data.
925 *Bioinformatics* **2014**, *30*, 1015–1016, doi:10.1093/bioinformatics/btt755.
- 926 48. Stone, E.A.; Sidow, A. Physicochemical Constraint Violation by Missense Substitutions
927 Mediates Impairment of Protein Function and Disease Severity. *Genome Res* **2005**, *15*, 978–986,
928 doi:10.1101/gr.3804205.
- 929 49. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.;
930 Kondrashov, A.S.; Sunyaev, S.R. A Method and Server for Predicting Damaging Missense
931 Mutations. *Nat Methods* **2010**, *7*, 248–249, doi:10.1038/nmeth0410-248.
- 932 50. Li, S.; Qian, D.; Thompson, B.A.; Gutierrez, S.; Wu, S.; Pesaran, T.; LaDuca, H.; Lu, H.-
933 M.; Chao, E.C.; Black, M.H. Tumour Characteristics Provide Evidence for Germline Mismatch
934 Repair Missense Variant Pathogenicity. *Journal of Medical Genetics* **2020**, *57*, 62–69,
935 doi:10.1136/jmedgenet-2019-106096.
- 936 51. Thompson, B.A.; Spurdle, A.B.; Plazzer, J.-P.; Greenblatt, M.S.; Akagi, K.; Al-Mulla, F.;
937 Bapat, B.; Bernstein, I.; Capellá, G.; den Dunnen, J.T.; et al. Application of a 5-Tiered Scheme
938 for Standardized Classification of 2,360 Unique Mismatch Repair Gene Variants in the InSiGHT
939 Locus-Specific Database. *Nat Genet* **2014**, *46*, 107–115, doi:10.1038/ng.2854.
- 940 52. Jaganathan, K.; Panagiotopoulou, S.K.; McRae, J.F.; Darbandi, S.F.; Knowles, D.; Li,
941 Y.I.; Kosmicki, J.A.; Arbelaez, J.; Cui, W.; Schwartz, G.B.; et al. Predicting Splicing from
942 Primary Sequence with Deep Learning. *Cell* **2019**, *176*, 535–548.e24,
943 doi:10.1016/j.cell.2018.12.015.
- 944 53. Scott, A.; Hernandez, F.; Chamberlin, A.; Smith, C.; Karam, R.; Kitzman, J.O.
945 Saturation-Scale Functional Evidence Supports Clinical Variant Interpretation in Lynch
946 Syndrome. *Genome Biology* **2022**, *23*, 266, doi:10.1186/s13059-022-02839-z.
- 947 54. Shirts, B.H.; Konnick, E.Q.; Upham, S.; Walsh, T.; Ranola, J.M.O.; Jacobson, A.L.;
948 King, M.-C.; Pearlman, R.; Hampel, H.; Pritchard, C.C. Using Somatic Mutations from Tumors
949 to Classify Variants in Mismatch Repair Genes. *Am J Hum Genet* **2018**, *103*, 19–29,
950 doi:10.1016/j.ajhg.2018.05.001.
- 951 55. Mensenkamp, A.R.; Vogelaar, I.P.; van Zelst-Stams, W.A.G.; Goossens, M.; Ouchene,
952 H.; Hendriks-Cornelissen, S.J.B.; Kwint, M.P.; Hoogerbrugge, N.; Nagtegaal, I.D.; Ligtenberg,

953 M.J.L. Somatic Mutations in MLH1 and MSH2 Are a Frequent Cause of Mismatch-Repair
954 Deficiency in Lynch Syndrome-like Tumors. *Gastroenterology* **2014**, *146*, 643-646.e8,
955 doi:10.1053/j.gastro.2013.12.002.
956 56. Elze, L.; Mensenkamp, A.R.; Nagtegaal, I.D.; van Zelst-Stams, W.A.G.; Dutch LS-Like
957 Study Group; de Voer, R.M.; Ligtenberg, M.J.L. Somatic Nonepigenetic Mismatch Repair Gene
958 Aberrations Underly Most Mismatch Repair-Deficient Lynch-Like Tumors. *Gastroenterology*
959 **2021**, *160*, 1414-1416.e3, doi:10.1053/j.gastro.2020.11.042.
960 57. Jia, X.; Burugula, B.B.; Chen, V.; Lemons, R.M.; Jayakody, S.; Maksutova, M.;
961 Kitzman, J.O. Massively Parallel Functional Testing of MSH2 Missense Variants Conferring
962 Lynch Syndrome Risk. *Am J Hum Genet* **2021**, *108*, 163–175, doi:10.1016/j.ajhg.2020.12.003.
963